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1. Introduction and aims 
Pharmaceutical analysis is one of the most challenging fields of analytical chemistry. 
Pharmaceutical analysts carry out the qualitative and quantitative control of APIs and drug 
products and also develop and validate appropriate methods. These methods are routinely 
used by manufacturing companies in process testing and by authorities for the quality control 
of drug products. In the vast majority of pharmaceutical analyses, instrumental analytical 
methods are applied. The most widespread of all techniques is HPLC, which is complemented 
or hyphenated with mass spectrometry, spectrophotometry, NMR or others. In consequence of 
its dominant role in the pharmaceutical industry, HPLC is developing with huge leaps 
nowadays. UHPLC is increasingly making conventional HPLC obsolete. The field of core-
shell particles, the application of new detection techniques or 2D chromatography and the 
very popular hyphenated systems provide many interesting problems or challenges. 
Nevertheless, it should not be forgotten that these development directions are very 
cost-intensive, as up-to-date instruments and even columns are very expensive. Smaller 
national pharmaceutical companies and state-financed control laboratories of national 
authorities therefore cannot always follow the development of instrumental analysis in this 
direction. One of my main goals was to develop modern, rapid, precise and reproducible, but 
also cost-effective HPLC assay methods which are generally available and applicable for 
most users. 
The development of sample preparation from complex drug products is the most 
challenging area of assay method development for HPLC. To demonstrate this, I have chosen 
to show two examples in my thesis. In the first example, the development problem relates to 
the separation of three physico-chemically different APIs of a multicomponent drug product. 
In the second example, the challenge is the complete recovery of the API from various 
complex suppository dosage forms manufactured with different bases. 
Even today a significant number of suppositories are prepared extemporaneously in 
Hungary. Most are prepared by clinical pharmacies for paediatric use. The magistral 
preparation of suppositories is cheap; moreover, customized personal therapy can be achieved 
much better through their use. On the other hand, the independent quality control of such 
products by authorities is not carried out at present. Accordingly, I would like to stress here 
how important this topic is and, by demonstrating the consequences of technological errors 
that may be committed during preparation, I would like to contribute to improving the quality 
of extemporaneous pharmaceutical manufacturing in pharmacies. 
2. LITERATURE  
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2. Literature 
2.1. Tested pharmaceutical dosage forms 
2.1.1. Oral powders 
An oral powder as a pharmaceutical dosage form containing solid, loose, dry ingredients, 
including one or more APIs with or without excipients. It is generally administered in or with 
water or another suitable liquid. It may also be swallowed directly. It is presented as single-
dose or multidose preparations. Multidose oral powders require the provision of a measuring 
device capable of delivering the quantity prescribed. Each dose of a single-dose powder is 
enclosed in an individual container, for example a sachet or a vial [1]. 
Oral powders are currently very popular dosage forms. Especially favoured are the 
granule forms of various OTC preparations, such as ACC®, Aspirin® or Neo Citran®. Their 
main advantage over compressed dosage forms is the larger specific surface, the less 
significant incompatibility issues and the comparative ease of adding taste maskers and 
colouring agents during formulation. When a rapid effect is desired, the API, for example an 
analgesic drug can be applied in oral powder dosage form (Flector®). 
2.1.2. Suppositories 
Suppositories are currently very popular formulations especially in paediatrics, where 
they can be used for the effective lowering of fever. The choice of a suppository as the mode 
of drug delivery is justified in all cases when oral delivery is impossible, that is an 
unconscious or vomiting patient, or in the case of infants. 
The therapeutic effect of correctly applied suppositories can be compared with that of 
injections because the API can penetrate from the lower tract of the rectum to the vena anales, 
thereby avoiding the vena portae and the liver, and can exert a systemic effect when 
transported to the vena cava inferior, so the API does not undergo a first pass effect 
(Figure 1). 
The therapeutic use of suppositories has another aspect worldwide at present. The 
suppository dosage form is widely used for various therapeutic indications, making use of the 
feature that the local effect of the suppository can be transformed into therapeutic benefit (e.g. 
in the treatment of asthma, ulcerative colitis, ulcerative proctitis or colorectal cancer in 
paediatric practice) [2-8]. The treatment of acute malaria in children requires combination 
2. LITERATURE  
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therapy in order to avoid the development of multidrug resistance. In these scenarios, it is a 
plausible solution to deliver one of the drugs of the combination in a suppository [9, 10]. Thus, 
a rapid systemic effect can be achieved. For the delivery of several non-steroid anti-
inflammatory drugs, such as paracetamol or indometacin, the efficacy of the suppository form 
is equivalent or superior to that of the oral route [11-14]. 
 
Figure 1 Potential uptake locations of the drug from the different sections of the rectum 
In Hungarian pharmaceutical practice, extemporaneous products including 
suppositories are just as popular as factory-produced medicines. Extemporaneous products 
comprise part of personal therapy, and take into account the physical status, age and other 
diseases of the patient. Extemporaneously produced pharmaceuticals are used particularly in 
paediatric clinical departments. 
Approximately 80% of the suppositories used in Central Europe are produced 
extemporaneously by moulding technique. In clinical pharmacies quantities of 100-300 and in 
independent pharmacies 10-12 suppositories are generally moulded as one batch. Suspension 
suppositories in particular are formulated with a solid fat vehicle (e.g. Witepsol 35) or a 
combination of this suppository base with surfactants [15]. The core of this technology is the 
dispersion of the finely powdered drug in the molten suppository base, after which the 
suspension is moulded under continuous stirring. The viscosity of fatty suppository bases is 
very low, and decreases still further with the increase of temperature, causing rapid 
sedimentation of the suspended particles and leading to an inhomogeneous product. When the 
liquid mass is moulded at around the solidification point, solidification occurs immediately 
when the mass enters the mould, making further additions of the base and drug impossible. In 
the calculation of the suppository base weight, Eq. 1 must be applied: 
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4 
 i
n
=i
im sfE=T ⋅−∑
1
 (1) 
where Tm is the suppository base to be weighed, E is the calibration constant of the mould, fi is 
the displacement factor of the ith component and si is the weight of the ith component. During 
the calculation of a correct formula, it is not sufficient to subtract the weight of the solid 
components from the final weight of the suppository to obtain the required amount of 
suppository base. We have to know the value of E for the specific mould and the specific 
suppository base, which can be determined through independent measurements. Ten 
suppositories are moulded with the mould, using the pure base, and after cooling they are 
weighed and the average suppository weight is calculated. This average value will be used as 
the calibration constant of the mould for the specific base. As the density of the API 
incorporated in the suppository can differ from that of the base, the displacement factor (f) is 
required to compensate the difference in densities. The value of f, which shows how much 
base will be displaced by unit weight of API, can be calculated from Eq. 2: 
 1
100
+
xG
G)(E
=f
⋅
−⋅
 (2) 
where E is the weight of the blank suppository containing only base, G is the weight of the 
suppository containing the API in known concentration, and x is the API content of the 
suppository in weight percentage. If the pharmacist fails to carry out the steps in strict 
accordance with the rules, significant deviations will be observed in the results of the 
homogeneity of the batch and in the total drug content of the batch. In pharmacies, the 
f values of the most frequent APIs in the most common bases are not generally available. 
According to good manufacturing practice, pharmacists apply the principle of overage during 
the calculation of the batch composition, but an incorrect calculation for the amount of vehicle 
required and other technological errors may lead to serious deviations in the final dosage for 
the individual suppositories [16-18]. 
In Hungarian pharmaceutical practice, moulded suppositories are formulated 
predominantly with three suppository bases: adeps solidus, massa macrogoli and W35TT, 
which contains surfactants. The lipophilic adeps solidus is officially included in Ph Eur as 
hard fat or Witepsol W35. Massa macrogoli is a hydrophilic base, which contains: macrogol 
1540 and Span 20. W35TT is a special lipohydrophilic base, which is included officially in 
FoNo. It is a mixture of 95 w/w% of hard fat, 2.5 w/w% of Tween 20 and 2.5 w/w% of 
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Tween 61. In consequence of procurement issues relating to Tween 61, Tween 60 is 
nowadays used instead. 
Numerous studies that have focused on the liberation of drugs from suppositories 
containing surfactants from the aspect of pharmaceutical technology have clearly revealed 
that it is beneficial for a suppository base to have high hydroxyl group content. The usage of 
non-ionic surfactants is now suggested, but in lower amounts than those used in older recipes, 
which generally means lower than 3%, and preferably around 1% [19]. A high surfactant 
concentration may lead to the formation of micelles, which incorporate some of the API, 
impeding its release [20]. According to Ghorab et al. [21], the optimum amount of Tween 60 
is 5%; higher proportions than that up to 10% had a lower effect on the release rate. Above 
10%, the release rate is decreased due to micelle formation. Surfactants not only enhance 
release of the drug from the suppository base, but increase the permeability of the tissues 
surrounding the rectal lumen. Non-ionic surfactant Tween 20 showed outstanding 
effectiveness when used in 5% combined with lipophilic vehicles [22]. 
2.2. Analysed drug substances 
2.2.1. Aminophenazone 
AMFZ is a phenazone derivative. It is a white crystalline powder 
which is soluble in water and freely soluble in alcohol. Its pKa is 4.70, 
and its log P is 0.99. AMFZ is an antipyretic and analgesic drug, for 
example in Demalgon® tablet or Germicid® suppository. This API is 
frequently used in clinical paediatric practice in Hungary, especially as 
an extemporaneous dosage form [23-26]. 
The antifebrile effect of AMFZ develops especially quickly (comparable to that of 
injections) if the drug is taken rectally. An additional benefit is that its administration does not 
require specially trained staff. Agranulocytosis, one of the registered side-effects of the 
substance, has a very low incidence, while carcinogenicity, another possible side-effect, can 
be completely eliminated through rectal administration [27-35]. During its biotransformation, 
AMFZ is demethylated in two steps, catalysed by cytochrome P450 2B [28, 29]. The 
demethylated product then undergoes acetylation and is eliminated from the body as 
acetylaminoantipyrine. In the presence of nitrite ion at pH between 2.0 and 3.1, the 
carcinogenic nitrosamine derivative dimethylnitrosamine is formed in parallel with the 
demethylation. The physiological circumstances in the stomach provide a suitable medium for 
 
N
N
O CH3
CH3N
CH3
H3C
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this reaction to take place [36-38]. On the other hand, rectal administration of AMFZ 
completely eliminates the possibility of dimethylnitrosamine formation as the pH of the 
mucous fluid in that region is around 7.9. 
2.2.2. Paracetamol 
Paracetamol or acetaminophen is one of the most frequently 
used antifebrile and painkiller drugs around the world. It has been 
used in Hungary only since 1990. It is incorporated in many well-
known products (Rubophen®, Panadol®, Coldrex®, Mexalen®, Miralgin®, Neo Citran® and 
Saridon®). It is an aniline derivative. It is a white, crystalline powder, which is moderately 
soluble in water and freely soluble in alcohol. Its calculated pKa is 9.48 and its log P value is 
0.53 [24, 26, 39]. 
Usually it is not classified as an NSAID because it does not show a significant anti-
inflammatory effect. In the event of an overdose, it causes acute liver failure. This is due to 
the saturation of conjugation with sulphate and glucuronide systems, which generate nontoxic 
metabolites, leading to the conversion of paracetamol to the highly reactive intermediate 
metabolite N-acetyl-p-benzoquinoneimine (NAPQI) via the cytochrome P450 2E1 and 3A4 
enzyme system, which becomes predominant. Excess amounts of NAPQI and glutathione are 
produced, which are responsible for decreased detoxification. Acetylcysteine can be used as 
the antidote of paracetamol toxication, which reduces paracetamol toxicity by rebuilding body 
stores of glutathione. Glutathione reacts with the toxic NAPQI metabolite so that it does not 
damage cells and can be safely excreted [40-42]. 
2.2.3. Acetylsalicylic acid 
ASA is a white, odourless, crystalline powder, which is slightly soluble 
in water and freely soluble in alcohol. It is used as a painkiller, antifebrile or 
anti-rheumatic drug. Its pKa is 3.83, and its log P is 1.25 [24, 26, 43]. 
For the mitigation of acute renal or gastrointestinal pain, the primary 
drug of choice is a NSAID such as ASA, paracetamol or ibuprofen [44]. 
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2.2.4. Papaverine 
Papaverine is a white, crystalline powder that is 
moderately soluble in water and alcohol. It is freely 
soluble in hot water. Its solubility can be increased by 
decreasing the pH of the aqueous medium. It is an alkaloid 
of opium. It has a smooth muscle relaxant effect [40, 45]. 
Its pKa is 6.12 and its log P is 3.92 [26]. A number of drug products are available on the 
market for the treatment of smooth muscle spasm, e.g. in the biliary, renal and intestinal tracts 
(BILA-GIT®). Such conditions are frequently treated with combined products, which contain 
a smooth muscle antispasmodic together with one or more NSAID painkiller drugs [46]. The 
combination of papaverine-HCl or papaverine base and ibuprofen or indometacin is nowadays 
commonly used, especially for the treatment of dysmenorrhoea. As regards the administration 
of papaverine, the research focus has shifted in recent years from the gastrointestinal tract to 
the coronary arteries [47] and the therapy of an erectile dysfunction [48-50, 40]. Nevertheless, 
in pharmaceutical practice, papaverine is still commonly prescribed as an antispasmodic to 
relieve gastrointestinal and menstrual spasms. 
2.3. Analytical methods 
2.3.1. Development of HPLC assay 
As an analytical technique, HPLC possesses a very impressive history, which has been 
extensively studied by many authors [51-55]. In my thesis, the focus is placed on the 
development of sample preparation methods and assay determination of pharmaceutical 
products. A deep theoretical introduction on the separation of small molecules will therefore 
not be included. 
One of the most important tasks of a chromatographic analyst in pharmaceutical R&D is 
the development of analytical methods for the assay of pharmaceutical products and 
validation of the methods before submission. 
The most challenging key step in this process, especially in the case of complex dosage 
forms (such as suppositories, extended release tablets, etc.), is the sample preparation. In this 
step, the API must be separated from the matrix, which can be a very complex task if both 
identification and quantitative determination are required. To achieve optimum recovery, the 
total API content of the product must be liberated. The European Pharmacopoeia does not 
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provide any guidance as concerns general sample preparation for the assay of any dosage 
form; details are included only in the pharmaceutical technological procedures. The US 
Pharmacopoeia, on the other hand, contains monographs about pharmaceutical products, 
including suppositories [16]. According to the literature, samples can be divided into 4 
groups: solid or liquid pharmaceutical products, biotechnological samples (proteins) or 
biological samples (blood, urine, tissue fluid, etc.). In the case of solid dosage forms, 
dissolution of the API from the finely ground powder of the sample with an appropriate 
solvent is necessary. It should be noted that the solvent must be compatible (miscible) with 
the chosen mobile phase of the chromatographic system. In the event of liquid dosage forms, 
this step is much simpler. On the other hand, solubility problems may arise, partition of the 
API between solvents of different polarity can be observed, or a change in solubility can 
occur with the change of pH. It may be generally stated that physical interactions of APIs and 
excipients that potentially cause problems during recovery are studied very rarely. Sample 
preparation should be handled within the scope of method development. 
During method development for HPLC, there are many options beyond those in the 
scientific literature to design or to predict the behaviour of the system. The main goal is 
always to separate the analytes from each other and from other components of the sample in a 
rapid, reproducible, accurate and robust method which provides optimum peak shape and 
theoretical plate number. 
HPLC method development is currently aided by many expert systems, such as the 
Pallas program package or the Marvin program package. In order to design the separation, it 
is necessary to know the basic physico-chemical parameters (log P, pKa and log D), which 
can provide guidance to reach the optimum method in the fewest development steps. log P 
determines the polarity of the compound, which is a fundamental parameter of the retention. 
pKa facilitates determination of the pH range in which a robust method can be developed, and 
also aids the choice of appropriate buffer system. log D describes the change in polarity of the 
compound vs. pH. It is a good indicator of how the retention may change in the studied pH 
range. The log D vs. pH function presents the distribution change of the dissociated and non-
dissociated forms. Thus, the mobile phase composition can be effectively designed on the 
basis of the predicted pKa and log D vs. pH curve, obtained from the expert system. In some 
cases, the sequence of elution of the components can also be effectively estimated. 
If the retention factors of the components differ too widely (k’1-k’2 > 10), it is suggested 
to apply gradient elution instead of isocratic elution. In gradient elution, the composition of 
the mobile phase is varied as a function of time. The application of gradients can effectively 
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decrease the retention of selected components if the concentration of the stronger component 
in the mobile phase is increased. 
2.3.2. The CMC and its determination 
One of the most characteristic properties of a surfactant is its CMC. In a specific solvent 
system, this is the concentration above which individual surfactant molecules spontaneously 
aggregate and form micelles through secondary interactions. Several methods are available 
for the determination of CMC. The most widely used techniques are the measurement of 
surface tension, conductance in the case of ionic surfactants, UV/VIS spectrophotometry, NIR 
spectroscopy, turbidimetry and densitometry [56, 57]. As the suppository base studied in the 
present work contained Tween 20 and Tween 60, in Table 1 the CMCs of these materials 
determined with different methods in previous studies are listed. 
Table 1 CMCs of Tween 20 and Tween 60 
TWEEN 20 
Reference Method Temperature Medium 
   H2O D2O Spec.
a 
[58] Surface tension RT 0.0804 - - 
[59] NIR RT 0.08 0.12 70 
[60] Surface tension RT 0.0488 - - 
[61] Densitometry 24.88 °C 0.097 - - 
[62] Surface tension RT 0.059 - - 
[63] 
Spectrophotometry of 
iodine absorbance 
RT 0.055 - - 
 Shift in λmax RT 0.0557 - - 
 Surface tension RT 0.0488 - - 
[64] Surface tension  RT 0.048 - - 
[65] Dye micellization RT 0.042 - - 
 Surface tension RT 0.011 - - 
TWEEN 60 
[61] Densitometry 24.88 °C 0.068 - - 
[63] 
Spectrophotometry of 
iodine absorbance 
RT 0.0209 - - 
 Shift in λmax RT 0.0196 - - 
 Surface tension RT 0.0206 - - 
[64] Surface tension RT 0.021 - - 
[65] Dye micellization RT 0.022 - - 
 Surface tension RT 0.0055 - - 
a1-ethyl-3-methylimidazolium bis(trifluoromethylsulfonyl) imide [EMIm]+[Tf2N]
-. 
When a colloidal solution is irradiated with visible light, the incident coherent beam is 
scattered. The intensity of the transmitted light is therefore lower than that of the incident 
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light, and scattered light can be detected in any direction around the incident beam. This 
phenomenon is called pseudoabsorbance or turbidity and is described by Eq. 3: 
 





tI
I
l
=τ 0ln
1
 (3) 
where τ is the turbidity, It is the intensity of the transmitted light, Io is the intensity of the 
incident light and l is the path length. As the light absorption properties of the colloidal 
solution before and after micelle formation differ, the rate of turbidity increase changes when 
the surfactant concentration is increased. This method therefore appeared appropriate for 
CMC determination. The intensity of the scattered light in connection with the turbidity of the 
solution is influenced by the size of the scattering particles, the difference between the 
refractive indices of the particles, the medium (contrast) and the interaction of the particles. In 
dilute solutions, interactions between particles can be neglected, and thus the increase in 
turbidity can be ascribed to the aggregation of the particles or in other words the formation of 
micelles [66]. 
2.3.3. Cerimetric titration of AMFZ 
The basis of the determination is a cerimetric redox titration method [67], during which 
the nascent oxygen evolved from the reaction of Ce(IV) with water oxidizes AMFZ. The end-
point of the titration is observed by the change in colour of ferroin present as indicator. 
N
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-4Ce3+-  4H+
+ 2H2O
 
 
The Ce(IV) ion oxidizes the water according to the following equations : 
 Ce4+  +  H2O
•• → Ce3+  +  [H2O
•]+ 
 [H2O
•]+ → HO•  +  H+ 
 2 HO• → H2O  +  O
•• 
The produced nascent oxygen (O••) oxidizes the pyrazolone ring to dioxypyramidone [68, 69]. 
AMFZ Dioxypyramidone 
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3. Materials and methods 
3.1. Materials 
The following materials were used in these studies: AMFZ (Sigma-Aldrich, St. Louis, 
MO, USA), paracetamol (Ph Eur 6.0, Phoenix Pharma Zrt., Hungary, Lot. No.: 1011204), 
papaverine-HCl (Molekula, Shaftesbury, UK), ASA (Ph Eur 6.0, University Pharmacy, 
University of Szeged, Szeged, Hungary), MeOH (Chromasolv for HPLC, Sigma-Aldrich, St. 
Louis, MO, USA), ACN (VWR, Prolabo, Fontenay-Sous-Bois, France), sodium acetate 
(Reanal, Budapest, Hungary), sulfuric acid 96% (Analyticals Carlo Erba, Milano, Italy), 
acetic acid 96% (VWR, Prolabo, Fontenay-sous-Bois, France), sodium hydroxide (Reanal, 
Budapest, Hungary), sodium chloride (VWR, Prolabo, Leuven, Belgium), potassium 
dihydrogenphosphate (Spektrum 3D, Debrecen, Hungary) and potassium hydroxide (Reanal, 
Budapest, Hungary), Suppositorium antipyreticum pro parvulo FoNo VII. (Naturland Ltd., 
Hungary, Lot. No.: 1938-1112 and Parma Produkt Ltd., Hungary, Lot. No.: 1209-1106). 
Throughout the experiments, HPLC grade solvents were used. The solvents and the aqueous 
solutions were prepared with triple distilled water. During the spectrophotometric 
measurements, MeOH (VWR, Prolabo, Fontenay-sous-Bois, France), TWEEN® 20 (Sigma-
Aldrich, St. Louis, MO, USA) and TWEEN® 60 (Sigma-Aldrich, St. Louis, MO, USA) were 
used.  
The suppository bases applied were hard fat and W35TT (University Pharmacy, 
University of Szeged, Szeged, Hungary). 
The divided powder samples in 4.1. Part I contained approximately 17.0 mg 
paracetamol, 26.0 mg ASA and 5.0 mg papaverine in a homogeneous mixture. For the stock 
solution, 48.0 mg powder was weighed with analytical precision into a 50.0 ml volumetric 
flask, dissolved and made up to volume with the solvent, phosphate buffer (25 mM, pH 
3.43) : ACN (85:15, V/V). During the preparation, the sample was heated to 40 °C, this step 
being required for the complete dissolution of ASA, which has low solubility (slightly soluble 
according to Ph Eur) in water. For the working sample solution, 3.0 ml stock solution was 
diluted to 10.0 ml and filtered through a 0.45 µm Millipore syringe filter before injection. 
Volumetric solutions for the cerimetric titrations in 4.3. Part III were prepared with the 
following materials: cerium(IV) sulfate tetrahydrate (Panreac, Barcelona, Spain), sulfuric acid 
96% (Farmitalia Carlo Erba, Milano, Italy) and ferroin-solution, 1/40 M (Reanal, Budapest, 
Hungary). 
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Factory-made suppositories were used during the comparison of the analytical methods. 
The reference product was Suppositorium antipyreticum pro parvulo FoNo VII. Naturland 
(Naturland Magyarország Kft., Budapest, Hungary), which contained 150 mg AMFZ per 
suppository in solid fat suppository base. One box contained six suppositories [70]. 
The studied samples in 4.3 Part III were prepared in regular pharmacies by a moulding 
technique, according to the following prescription. Ten suppositories were prescribed with a 
labelled claim of 100 mg AMFZ in each suppository. The choice of vehicle for the 
suppository was left to the responsibility of the pharmacist. Practically all of the samples were 
prepared with solid fat. In each case, predetermined technological errors (known to us) were 
made during the manufacturing samples. 
3.2. Methods 
3.2.1. Preparation of reference solutions and establishment of system suitability 
The API contents of the samples were quantified by reference to reference solution in 
the appropriate solvent mixtures with concentrations presented in Table 2, which 
corresponded to the theoretical 100% concentration level of the sample solutions to be 
examined. Two reference solutions were prepared from independent stock solutions in order 
to check the system suitability by the following procedure. 
Table 2 Concentrations of standard APIs 
 Concentration (mg/ml) Solvent 
Divided powder  
Paracetamol 0.100 
Phosphate buffer (25 mM, 
pH 3.43) : ACN (85:15, V/V) 
ASA 0.150 
Papaverine 0.030 
Suppository 
AMFZ 0.075 MeOH: water (50:50, V/V) 
Paracetamol 0.075 
MeOH : ACN : 50 mM 
phosphate buffer (pH 6.3), 
(50:5:45, V/V/V) 
The precision of the injections was checked before all measurement sets by injecting the 
first reference solution 5 times. The system was considered suitable if the RSD% of the 5 
replicate injections did not exceed 2.0%. The accuracy of the calibration was checked by 
injecting the second reference solution twice. The results were accepted if the correlation 
factor (see Eq. 4) calculated from the average response ratio of the two reference solutions 
was not more than 2.0. 
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 Correlation factor %100
wA
wA
1 
Std1Std2
Std2Std1 ⋅
⋅
⋅
−=  (4) 
where AStd1 and AStd2 are the average peak areas of the replicate reference injections, while 
wStd1 and wStd2 are the weights of the reference substances used to prepare the solutions. 
The symmetry factor of the main peak of interest was also monitored throughout the 
measurements; it had to be between 0.7 and 2.0 for the analysis to be started. 
3.2.2. Titrimetric analysis of suppositories with AMFZ 
During the sample preparation, 1 suppository was melted over a 40 °C water bath and 3 
replicate samples of 0.20-0.30 g were weighed from the molten mass into titration flasks. 
10.0 ml of 15% sulfuric acid was added to each sample and the mixture was heated to 40 °C 
to extract the API from the suppository base. The mixture was then cooled to room 
temperature, 15 ml of distilled water was added, and after mixing and the addition of 1 drop 
of ferroin indicator, titration with 0.05 M cerium(IV) sulfate volumetric solution was 
performed until the colour of the solution changed from orange to green and remained green 
for at least 1 min. 
3.3. Instruments and other equipment 
For mobile phase degassing and sample sonication a DLS 310-T DONAU-LAB-SONIC 
US bath was used. 
HPLC measurements were carried out on a Shimadzu Prominence UHPLC system 
(Shimadzu Corp., Kyoto, Japan) equipped with an LC-20AD pump, a 4-port solenoid mixing 
valve, a CTO-20A column oven, a DGU-20ASR degasser, and an SPD-M20A UV/VIS PDA 
detector with a 10 mm optical path length flow cell. Samples were injected via a Rheodyne 6-
port manual injector valve fitted with a 20 µl sample loop. Separation was studied on a 
Hypersil ODS (C18) 150x4.6 mm, 5 µm column (Thermo Scientific, Keystone, UK), a Luna 
C18(2), 150x4.6 mm, 3  µm column (Phenomenex, Torrance, CA, USA) and a Zorbax SB-
C18 150x4.6 mm, 3.5 µm column (Agilent, Santa Clara, CA, USA) during the method 
development procedure. Data acquisition and peak integration were carried out with 
LCSolution (Shimadzu Corp., Kyoto, Japan) chromatographic data acquisition and processing 
software. The results were evaluated with LC Solution and Microsoft Office Excel 2007 
software. The log D vs. pH functions for the tested compounds were predicted with Pallas 
intelligent chromatographic software [26]. 
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Spectrophotometric measurements were carried out on a Shimadzu UV-1601 UV/VIS 
double-beam spectrophotometer. Throughout the measurements, quartz cells with 10 mm 
optical path length were used. The spectrophotometric data were evaluated with Microsoft 
Excel. 
1H NMR spectra were recorded on a BRUKER Avance DRX 500 spectrometer at room 
temperature, with a deuterium lock. There was no water suppression during the experiment. 
The carrier frequency (O1) was placed at 7.01 ppm and a 16.00 ppm wide region was detected, 
the excitation was carried out with a 30° pulse (PW90=12.5 µs), the interpulse delay was set to 
3 seconds, the acquisition time was 2.05 s and 8 transients were collected into 32K data points. 
The spectral processing included an exponential filtering with 0.3 Hz, zero-filling to 64K data 
points and a complex Fourier transformation. The data collection and data processing were 
carried out with Bruker XWIN-NMR 3.1 software. 
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4. Results 
4.1. Part I. Development and validation of HPLC assays 
4.1.1. Chromatographic separation problems of drugs with different polarities 
Many authors have described the simultaneous determination of paracetamol and ASA 
in various pharmaceutical dosage forms and also in blood or urine samples [71–81], but the 
available literature on the HPLC analysis of papaverine is quite limited. Mostly, the presence 
of papaverine together with opiates has been studied [82–90] and many findings are available 
as concerns its identification in blood samples from opiate drug users [83, 86, 87, 89, 90]. It is 
very rarely detected by means of UV/VIS photometry in chromatographic methods. 
 
Figure 2 log D vs. pH curves of paracetamol, ASA and papaverine 
4.1.1.1. Method development strategy 
As the first step of chromatographic method development, the chemical properties of 
the drugs, which may influence the separation, were determined. Particularly the separation of 
papaverine and ASA can be difficult to achieve, in view of the specific pKa values and the 
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log D vs. pH curves (Figure 2). The pH of the applied aqueous mobile phase was one of the 
key parameters that affected the separation. The range between 2 and 8 was optimum from the 
aspect of the stationary phase, but the range between 1 and 6 was not appropriate for the 
separation of papaverine, which contains 1 basic nitrogen with a pKa in the upper part of the 
range. The ratio of dissociated and undissociated forms of ASA changes in the pH range 3-8. 
At pH > 6 (which is beneficial for papaverine separation), ASA peak splitting was observed 
[26]. 
In light of the above findings, the most challenging task was to find the most 
appropriate combination of the boundary conditions, where the overall negative influence on 
the separation and elution of the analytes was least. pH 3.4 ± 0.05 was found to be a 
reasonable compromise for the pH of the aqueous phase. An assay of papaverine alone was 
reported in the application database of Agilent, which involved a similar pH in the aqueous 
mobile phase [91]. In this method, the aqueous eluent contained 25 mM potassium 
dihydrogenphosphate, but sulfuric acid was used to adjust the pH so as not to increase the 
phosphate concentration. 
 
Figure 3 Chromatograms obtained on Hypersil ODS (a), Luna C18 (b) and Zorbax SB-18 (c) columns. 
Coeluting peaks are magnified in the insets 
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It can be seen in Figure 2 that at pH 3.4 paracetamol and most of the ASA are in an 
undissociated form. The basic papaverine is at the beginning of the transient section of the 
equilibrium, which can be observed between pH 3 and 6 in the log D curve. The ratio of the 
organic modifier of the mobile phase, ACN, was linearly increased from 7% to 80% during 
the initial 16 min of the run time, and was then kept constant for 4 min. Between 20 and 22 
min, the ratio of the organic modifier was linearly decreased to the initial level, at which it 
was held constant during the remainder of the run, to 25 min. A 1:1 (V/V) mixture of MeOH 
and the mobile phase was suggested as solvent in the literature method. The flow rate of the 
mobile phase was 1.5 ml/min and the separation was achieved on a Hypersil ODS column at 
60 °C. The results of the runs under the above-described conditions can be seen in 
chromatogram (a) in Figure 3, where paracetamol and ASA were co-eluted. An initial 
isocratic hold was therefore inserted into the method before the gradient for the resolution of 
the co-elution, because the lower organic content selectively increased the retention times of 
the peaks, removing them from the void. In the new method, a constant 7% ACN section was 
applied during the initial 2 min, followed by a similar gradient as described above. At this 
point it became obvious that the hydrophobicity of the stationary phase was too low and the 
retention of basic papaverine was too high, so that it could not be eluted with acceptable peak 
shape within reasonable time, although the separation of the paracetamol and the ASA was 
ideal. 
 
Figure 4 Selectivity and hydrophobicity comparison of the three columns in the database of Waters 
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For optimization of the peak shape, an alternative column had to be used. Two columns 
with different selectivity and higher hydrophobicity than that of the Hypersil ODS column 
were chosen on the basis of the data to be found in the comparative column selectivity 
database of Waters [92] (Figure 4), the Luna C18(2) and the Zorbax SB-C18 stationary 
phases. It is clear from chromatogram (b) in Figure 3 that a hydrophobicity increase of less 
than one order of magnitude led to the successful elution of papaverine. This latter method 
resulted in the co-elution of ASA and papaverine on both columns. In order to resolve the 
peaks, the ACN content at the end of the gradient and in the second isocratic section had to be 
decreased from 80% to 25%. 
This modification resulted in suitable separation for all three analytes on both Luna 
C18(2) and Zorbax SB-C18. ASA and the papaverine were eluted with higher resolution on 
the more selective Zorbax SB-C18 column. The retention parameters of the separated peaks 
on the three different columns are presented in Table 3. It is clear that the Hypersil ODS 
column was not suitable for the simultaneous separation of the three components, whereas the 
Luna C18 and Zorbax SB-C18 columns were equally appropriate; nevertheless, the results 
obtained on the Zorbax SB-C18 column were superior to those on the Luna C18 stationary 
phase as concerns its higher selectivity. Sample chromatograms measured on the three 
columns are presented in Figure 5. 
 
Figure 5 Comparison of the three stationary phases. It can be observed that papaverine was completely 
retained on Hypersil ODS 
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Table 3 Chromatographic parameters of the sample peaks on the three columns; k’ is the retention factor, 
α the separation factor, Rs the resolution and tR the retention time 
Column type Parameter Paracetamol ASA Papaverine 
Hypersil ODS 
k’ 0.549 2.866 - 
α 0.000 5.224 - 
R - 25.511 - 
tR 2.323 5.799 - 
Luna C18 
k’ 1.324 3.487 3.937 
α 0.000 2.634 1.129 
R - 29.949 7.039 
tR 3.486 6.731 7.406 
Zorbax SB-C18 
k’ 0.662 2.932 4.102 
α 0.000 4.432 1.399 
R - 30.844 16.192 
tR 2.492 5.897 7.653 
4.1.1.2. The developed method 
The mobile phase during the quantitative determination was a potassium 
dihydrogenphosphate (25 mM, pH 3.43) : ACN mixture. The details of the solvent gradient 
are to be seen in Table 4. The buffer was prepared with potassium dihydrogenphosphate, and 
the pH of the solution was adjusted to the desired value with 1 M sulfuric acid solution. The 
flow rate was 1.5 ml/min, the run time was 10 min and the column temperature was 60 °C. 
The chromatograms were recorded at 240 nm, at which wavelength all three components can 
be detected reproducibly. The choice of the detection wavelength was limited by the molar 
absorptivity of ASA, which is about one order of magnitude lower than those of the other 
components [93]. Although ASA is the main component of the mixture, its peak intensity is 
lower than that of paracetamol. During runs, the UV spectra (200-300 nm) of the components 
were collected for identification of the drugs. The column applied during method validation 
was the Zorbax SB-C18 150x4.6 mm, 3.5 µm column. 
Table 4 Solvent gradient in the chromatographic method described in section 3.1 
Time ACN % 
0.00 7 
2.00 7 
4.00 25 
8.00 25 
8.10 7 
10.0 7 
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4.1.1.3. Validation 
A full validation of the method according to ICH guideline Q2 (R1) [94] is presented 
here. The performance characteristics linearity, repeatability, intermediate precision, accuracy, 
specificity and robustness were tested. As the method was to be utilized for the rapid quality 
control of dosage units, which does not require the method to be stability-indicating, forced 
degradation studies were not conducted [95]. 
Linearity 
The linearity of the method was examined in the concentration range between 0.02 and 
0.04 mg/ml in the case of paracetamol, between 0.03 and 0.065 mg/ml for ASA and between 
0.006 and 0.013 mg/ml for papaverine, these data corresponding to 70-130% of the nominal 
contents of the dosage units. The range was covered by use of six solutions, each diluted from 
two individually prepared reference solutions, so that the sequence of the stock solutions used 
for the dilutions alternated. The peak areas determined with LCSolution were plotted versus 
the concentrations of the solutions and a straight line was fitted to the points. The slope of the 
paracetamol fitted straight line was found to be 2.0171·108, the intercept was 1.5172·103 and 
R2 was 0.9995. The slope of the fitted straight line in the case of ASA was found to be 
4.9169·107, the intercept was 4.9344·104 and R2 was 0.9997. Finally, the slope of the fitted 
straight line for papaverine was found to be 3.1811·108, the intercept was -3.6861·104 and R2 
was 0.9997. This demonstrated that in the studied concentration range the response of the 
method was linear. 
Precision/ Repeatability 
Repeatability was checked on six individual samples according to the method described 
in section 3.1. For paracetamol and ASA, RSD% proved to be 0.4% and 0.6%, respectively, 
both of which are acceptable. The papavarine results gave the highest RSD%, 1.4%, but this is 
also acceptable when the very low nominal amount of drug in the sample is taken into 
consideration. 
Precision/ Intermediate precision 
The same analysis procedure was carried out by a different analyst on a different day, 
using a freshly prepared mobile phase. The results for the paracetamol component were an 
RSD% of 0.7% and a relative difference of 1.3% between the averages of the repeatability 
(Day 1) and intermediate precision (Day 2) results compared to the mean of the average 
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values measured for each. Both results can be accepted according to the principles of general 
pharmaceutical analytical practice. For the ASA, the RSD% of the individual results was 
0.9%, while the relative difference between the repeatability and intermediate precision was 
1.2%. For papaverine, the RSD% proved to be 2.1% and the relative difference of the mean 
values on the two days was also 2.1%. All three results are in accordance with the appropriate 
guidelines, and were therefore accepted. 
Accuracy 
The accuracy of the method was studied in the range between 70% and 130% of the 
nominal content of the powder. The results are shown in Table S-1. Although all of the 
average values fell between 95% and 105%, it should be mentioned that in the cases of ASA 
and papaverine most of the averages were below 100%, while in the case of paracetamol they 
were above 100%. This may raise a warning flag, but no trend was observed within the results 
that could be correlated with the increasing concentration of the sample groups. 
Specificity 
When the procedure was carried out with solvent as blank (the sample contained the 
API without excipients), no peak was detected at the retention times of the drugs. 
Robustness 
Examinations were made of the effects of changing the organic : aqueous ratio in the 
isocratic phases of the gradient, the pH of the aqueous phase, the flow rate of the mobile 
phase and the temperature of the column on the retention time and on the shapes of the 
analyte peaks. The results of the robustness studies (Table S-2, Figure 6) demonstrate that 
the ratio of the aqueous and organic phases exerted a great influence on both the retention 
time and the peak symmetry of the analyte. Variation of the pH of the aqueous phase caused 
only minor shifts in the retention times of the paracetamol and ASA peaks. The elution of 
paracetamol was not influenced by this parameter at all. In the cases of ASA and papaverine, 
the shift of the retention time in the opposite direction with the increase of pH caused an 
increase in resolution, which is in agreement with the increasing polarity of the components 
with pH. The flow rate change caused a minimal change in the retention time, proportional to 
the extent of the change. Flow rate changes did not influence the peak shape or plate numbers. 
Changes in column temperature did not cause significant changes in the retention times.  
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Figure 6 Robustness test results 
Nevertheless, it is noteworthy that the retention of papaverine decreased with the 
decrease of temperature. Finally, variation of the organic : aqueous ratio, both at the start and 
at the end of the gradient, caused considerable changes in the peak retention times. Decrease 
of the organic modifier content of the initial hold increased the retention of paracetamol, 
while increase of the organic component pushed the peak very close to the void peak. 
Decrease of the organic modifier content at the end of the gradient increased the retention of 
both ASA and papaverine, this being more significant in the case of papaverine. On the other 
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hand, the papaverine peak shape became more asymmetric and the number of theoretical 
plates also decreased in this case. A change in the opposite direction led to decreases in the 
retention time of ASA and papaverine, the greater effect being observed for papaverine, and 
in this case the two peaks eluted too close to each other. This last change did not influence the 
retention of paracetamol; only a slight increase in the theoretical plate number was observed. 
The results reveal that the method is robust, and the peaks are well separated and elute with 
acceptable symmetry within the studied boundaries of the parameters. 
4.1.2. Chromatographic assay of AMFZ and paracetamol for suppository study 
Due to the complex nature of suppository matrices, a fast and efficient HPLC assay 
method was required to control the development of sample preparation. In the following 
subsections, the results of the development is presented.  
4.1.2.1. Method development for AMFZ 
A current, rapid, effective and state-of-the-art reversed-phase chromatographic method 
for instrumental routine analysis of suppositories containing AMFZ was to be set up. The 
literature search revealed that methods for the HPLC analysis of AMFZ were very rare and 
those found related to very low concentrations in biological fluids or tissues. On the other 
hand, many hits were found for the HPLC analysis of the pyrazolone derivative metamizole in 
tablet formulations, which could shed light on the initial steps of method development for 
AMFZ [96-103]. 
The stationary phase was chosen on the basis of the work of El Seikh et al. [96], but the 
initial scouting experiments revealed that the composition and the pH of the mobile phase had 
to be changed considerably. With MeOH–acetic acid (pH 2.78; 1.0%) (70:30, V/V) as mobile 
phase, the AMFZ peak eluted between 15 and 30 min and showed significant asymmetry 
(Figure 7). It was obvious that the mobile phase composition described by El-Seikh et al. 
would have given a much longer retention time. Simulations carried out with the Pallas 
software [26] showed that the pH of the aqueous part of the mobile phase should be > 4.5 to 
achieve acceptable robustness and peak shape (Figure 8). 
A set of experiments was therefore designed using MeOH–sodium acetate buffer (pH 
4.5 or 5.0; 0.05 M) (50:50 or 60:40, V/V) as mobile phase in various combinations. The shape 
of the AMFZ peak in the resulting chromatograms improved on increase of both the pH and 
the proportion of MeOH. 
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Figure 7 Initial chromatogram of development 
 
Figure 8 log D curve of aminophenazone by Pallas 
In the final experiment, with MeOH–sodium acetate buffer (pH 5.5; 0.05 M) (60:40, 
V/V) as eluent, the symmetry factor of the AMFZ peak proved to be 1.43, and the peak width 
measured at the baseline was 0.2 min. It still seemed plausible to use acetate buffer at pH 5.5, 
where it has a somewhat lower buffer capacity, but the chosen concentration of 0.05 M 
compensated this.  
4.1.2.2. Final assay for AMFZ analysis 
The mobile phase was MeOH–sodium acetate (pH5.5; 0.05 M) (60:40, V/V). The pH of 
the sodium acetate buffer solution was set to 5.5 with acetic acid. The flow rate of the 
reversed-phase isocratic eluent was 1.5 ml/min and the run time was 5 min. The 
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chromatographic column was thermostated at 30 °C. The chromatograms were recorded at 
243 nm. The retention time of aminophenazone was 1.8 min. 
4.1.2.3. Development of a HPLC method for paracetamol assay 
The method development was based on the parameters described in the literature. 
Phosphate buffer was prepared by mixing aqueous 0.05 M phosphoric acid solution with 0.2 
M sodium hydroxide solution to reach pH 6.3 [77].  
The isocratic mobile phase applied was a mixture of phosphate buffer (pH 6.3) and 
ACN (90:10) (V/V), filtered and degassed. The separation of the API was originally achieved 
on a Hypurity Advance column (150 x 4.6 mm, 5 µm, Thermo-Hypersil Keystone, Bellefonte, 
PA, USA, with a polar amide group embedded within a C8 chain). The flow rate was 
1 ml/min, and the injection volume was 20 µl. The detection wavelength was set at 220 nm. 
The sample to be separated contained paracetamol and tramadol hydrochloride as APIs. The 
peak features of paracetamol were a retention time of 3.65 and a selectivity (α) of 2.50. 
In the developed method, four parameters were refined. The isocratic elution remained, 
but the preparation of the aqueous phase was modified. The new buffer was prepared from 
50 mM potassium dihydrogenphosphate, with the pH set to 6.3 ± 0.05 with 5 M potassium 
hydroxide solution. The final aqueous : organic ratio remained at 90 : 10, with ACN as the 
organic modifier. The application of potassium dihydrogenphosphate was necessary, because 
appropriate HPLC grade phosphoric acid was not available on stock. 
The next modification was the change of the stationary phase. In the original method, 
the authors used a C8 column with an embedded polar group, but this was needed only for the 
separation of the other component (tramadol), and not for the retention of paracetamol. A general 
C18 column, Thermo Scientific Hypersil ODS, 150 x 4.6 mm, 5 µm, was therefore chosen. 
Furthermore, the flow rate was increased from 1 ml/min to 1.5 ml/min, the retention time of 
the paracetamol then decreasing to 2.4 min. The shorter running time (5 min instead of the 
original 8 min) was more plausible because the tested samples were monocomponent, and 
more injections could be completed within a given time in the absence of an autosampler. The 
detection wavelength was set to 241 nm because paracetamol has an absorption maximum at 
this wavelength (Figure 9). 
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Figure 9 UV spectrum of paracetamol in MeOH 
4.1.2.4. Final assay for paracetamol analysis 
The mobile phase during the quantitative determination of paracetamol was ACN–
potassium dihydrogenphosphate (pH 6.3; 0.05 M) (10:90, V/V). The buffer was prepared with 
potassium dihydrogenphosphate and the pH of the solution was adjusted to 6.3 with 1 M 
potassium hydroxide solution. The flow rate, the run time and the column temperature were 
the same as described in subsection 4.1.2.2. The chromatograms were recorded at 241 nm. 
The retention time of paracetamol was 2.3 min. 
4.1.2.5. Validation 
Full validation of both methods described in subsections 4.1.2.2 and 4.1.2.4 according 
to ICH guideline Q2 (R1) [94] has been carried out. The following performance 
characteristics have been studied: linearity, repeatability, intermediate precision, accuracy, 
specificity and robustness. As the methods were to be used for the rapid quality control of 
dosage units, which did not require the method to be stability-indicating, forced degradation 
studies were not conducted [95]. 
The repeatability, intermediate precision, accuracy and specificity studies were carried 
out with three vehicles in the case of AMFZ and with W35TT in the case of paracetamol. 
These vehicle specific results are shown in section 4.2.6. 
Linearity 
AMFZ method 
The linearity of the method was examined in the concentration range between 0.025 and 
0.150 mg/ml, which corresponds to 50-450% of the nominal content of the suppositories. The 
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higher limit was chosen with regard to the fact that initial experiments gave individual results 
in this concentration range. Thus, it was necessary to check the method at extremely high 
active substance concentrations. The range was covered by 7 solutions each diluted from 2 
individually prepared reference solutions so that the sequence of the stock solutions used for 
the dilutions alternated. The peak areas determined with LCSolution were plotted versus the 
concentration of the solutions and a straight line was fitted to the points. The slope of the 
fitted straight line was found to be 3.498·107, the intercept was -5.165·104 and R2 was 0.9998. 
This proved that in the proposed concentration range the method was linear. 
Paracetamol method 
The linarity of the method was tested analogously to AMFZ. Linearity samples were 
prepared from 2 standard solutions, 0.5 mg/ml (A) and 0.6 mg/ml (B) paracetamol in MeOH. 
7 solutions were prepared, which corresponded to 50-300% of the nominal content of the 
suppositories and using both individually prepared stock solutions alternatively. The target 
concentration was 0.05 mg/ml. The slope of the fitted straight line was found to be 6.210·107, 
the intercept was 7.474·104 and the goodness of fit, expressed by R2, was 0.9963. This proved 
that in the proposed concentration range the method was linear. 
Stability of standard and sample solutions 
Table 5 Results of solution stability studies 
Time/hours 
Standard solution Sample solution 
Area 
Relative 
difference % 
Area 
Relative 
difference % 
0 2903843 - 2076275 - 
18 2909154 0.2 2075720 0.0 
24 2904895 0.0 2073721 -0.1 
39 2902092 -0.1 2074466 -0.1 
48 2904450 0.0 2073840 -0.1 
63 2906272 0.1 2074709 -0.1 
72 2903753 0.0 2080587 0.2 
96 2904386 0.0 2077305 0.0 
Only the AMFZ samples were tested in this respect. The stability of the standard 
solution and the sample solution was studied for 4 days. Both solutions were stored in a 
refrigerator between 2-8 °C. The acceptance criterion was set up according to the relative 
difference value shown below: 
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 100 difference Relative ⋅
−
Start
StoredStart
A
AA
=  (6) 
The solution was considered stable as long as the relative difference at a specific time 
point was not more than 3.0%. On the basis of the data presented in Table 5, the standard 
solutions can be considered stable for at least 96 h, and the sample solutions can be 
considered stable for at least 96 h. 
Robustness 
The effects of changing the organic–aqueous ratio, the pH of the aqueous phase, the 
flow rate of the mobile phase and the temperature of the column on the retention time and on 
the shape of the AMFZ and paracetamol peaks were examined. The results of the robustness 
studies presented in Table S-3 demonstrate that the ratio of the aqueous and organic phases 
exerted a great influence on both the retention time and the peak symmetry of the analytes. 
Overlaid chromatograms of the robustness study in the case of AMFZ are shown in Figure 10 
to provide a more straightforward visual display of the tabulated data. It can be seen that the 
pH of the aqueous phase significantly changed the symmetry of the peak, which is in 
accordance with the results obtained from the simulations with the Pallas software. The lower 
the pH, the more asymmetrical the peak was. On the other hand, the pH of the mobile phase 
had only a very slight effect on the retention time of the peak. The flow rate influenced the 
retention time, as expected, while it had a negligible effect on the peak shape. The column 
temperature did not influence either the retention time or the symmetry of the main peak. 
The overlaid chromatograms of the paracetamol robustness study are shown in 
Figure 11. Changing the pH of the aqueous component of the mobile phase did not influence 
the retention parameters of paracetamol significantly. On the other hand, higher temperature, 
a higher organic ratio in the eluent and a higher flow rate of the eluent significantly decreased 
the retention time. The change in the aqueous organic ratio affected the peak shape of 
paracetamol strongly, which changed from 0.911 to 1.215 during the experiments. In all other 
cases, the symmetry of the peak remained stable around 1.15. 
 It can be stated on the basis of the above data that the developed methods are robust 
within the studied parameter ranges. 
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Figure 10 AMFZ robustness test results 
 
Figure 11 Paracetamol robustness test results 
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4.2. Part II. Challenges in the development of sample preparation for 
suppositories  
4.2.1. Suppositories without surfactants 
Magistral prescriptions do not usually specify the suppository base to be used as vehicle 
and it is left to the pharmacists to apply their professional knowledge to choose the most 
suitable one from the possibilities listed in the official Pharmacopoeia. The development of 
the sample preparation involved in particular two suppository vehicles, adeps solidus and 
massa macrogoli, as these are the most commonly chosen ones. The same MeOH–water 
solvent mixture (50:50, V/V) was used for both vehicles. However, the methods differed as 
concerns other aspects of the sample preparation. This is due to the fundamentally different 
physico-chemical properties of these two vehicles. 
Adeps solidus and massa macrogoli cannot be distinguished by purely organoleptic 
examination. In the first step of sample preparation, the suppository (containing the 
unindentified vehicle) was weighed in a beaker, 15 ml of the above solvent mixture was 
added, and the beaker was heated in a 40 °C water bath until the suppository melted. (At this 
point, the behaviour of the molten suppository revealed its nature. In the case of adeps solidus, 
a consistent, clear, colourless fatty phase appeared on the surface of the solvent mixture, 
whereas with massa macrogoli the solution became homogeneous and clear and no second 
phase could be observed. In some cases, massa macrogoli may contain a certain amount of 
tensides, when the resulting solution was opaque, but even then no second phase or fat 
droplets could be observed.) At this stage, the active substance was extracted from the vehicle 
by shaking the sample for 10 min. 
The massa macrogoli-based samples did not require filtration, so the solution was 
transferred directly into a 50 ml volumetric flask and the beaker was rinsed with another 
15 ml and then 2 x 5 ml of solvent mixture, the rinsing solvent likewise being transferred to 
the volumetric flask, the solution next being made up to volume with the solvent mixture.  
The adeps solidus-based samples required removal of the fatty phase by freezing on an ice-
bath, when the fat solidified and the liquid could be decanted into a 50 ml volumetric flask. 
This extraction step was repeated with a second 15 ml portion of solvent mixture in a 40 °C 
water bath. The beaker was finally washed twice with 5 ml of solvent mixture, which was 
transferred to the volumetric flask, the solution then being made up to volume with the 
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solvent mixture. The outstanding benefit of this sample preparation procedure is that it does 
not require an initial knowledge of the suppository base used.  
Finally, in both cases a 0.3 ml aliquot of the stock solution was transferred to a 10 ml 
volumetric flask and made up to volume with the solvent mixture. The solution was filtered on 
a Millipore Millex PVDF membrane filter with a pore size of 0.45 µm. 
4.2.2. Surfactant-containing suppositories 
As W35TT is based on hard fat, it seemed reasonable to choose the sample preparation 
method described in section 4.2.1 for hard fat as the starting point for the development. 
However, our expectations were not fulfilled; the recovery of the API from the W35TT base 
was only 88%. It was hypothesized that the surfactants formed micelles within the 
suppository base, which encapsulated some of the API. The sample preparation procedure 
described in section 4.2.1 for hard fat was not suitable for quantitative release of the drug 
from the micelles for the analysis. This caused the difference in recovery between the two 
bases. In order to achieve a satisfactory release, the micelles had to be broken down to gain 
access to the entrapped drug. It was presumed that salting-out might be a suitable method to 
solve this problem. 
4.2.2.1. Effect of sodium chloride concentration on drug recovery 
The procedure applied in the case of hard fat was amended with an additional step by 
adding sodium chloride solution in increasing concentrations to the first 15 ml of solvent in 
order to study the micelle-opening effect of salting-out. The sodium chloride concentrations 
applied were 0, 50, 100, 150 and 200 mM. At all levels, two parallel samples were prepared. 
HPLC analysis revealed that the recovery from all of the samples remained below 95%. 
Figure 12 demonstrates that the increasing sodium chloride concentration did not correlate 
with the observed recovery change. Calculated covariance between the concentrations and the 
recoveries suggested a slightly increasing relationship, which was possibly due to the minor 
CMC-decreasing effect of strong electrolytes [103, 104]. The question may arise as to 
whether further increase of the sodium chloride concentration might have improved the 
recovery sufficiently. The answer is a clear no because higher sodium chloride concentration 
would probably have caused the precipitation of the salt in the mobile phase as sodium 
chloride has a solubility one order of magnitude lower in MeOH than in water, making the 
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analysis impossible. Precipitation could have damaged the silica core of the column, or could 
have caused clogging in the flow lines; therefore, higher salt concentrations were not tested. 
 
Figure 12 Recovery of AMFZ and paracetamol. (a) Effects of NaCl concentration. (b) Effects of pH. (c,d) 
Effects of pH at constant c(NaCl) = 100 mM. Vertical bars denote means of 3 independent measurements 
(n=3), error bars indicate the standard deviation of the 3 data. Covariances between the independent 
variable (concentration) and the dependent variable (recovery) for plot a=28.67; b=-13.47; c=58.71 and 
d=75.38 
4.2.2.2. Effect of pH change on drug recovery 
Micelle formation can be influenced by change of pH [105]. The API recovery was 
therefore studied in analytical samples containing increasing sodium hydroxide concentration. 
The additional step in this case was the addition of 5 M sodium hydroxide solution to the 
initial 15 ml of extraction solvent during the melting of the suppository. Three parallel 
samples were prepared, in which the concentrations were 0, 20, 40, 60 and 80 mM. The 
HPLC analysis indicated that none of the recovery results reached the lower limit of the 
required range of 95-105% at any sodium hydroxide concentration. Similarly to the sodium 
chloride concentration study, these recovery values did not exhibit any correlation with the 
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increasing base concentration. The covariance of the series of data (see caption of Figure 12) 
indicates a negative relationship. Therefore, higher sodium hydroxide concentrations were not 
studied. 
4.2.2.3. Effect of US treatment on drug recovery 
Micelles can be effectively destroyed by US treatment. Due to the ineffectiveness of pH 
change and salting out, 30 min ultrasound was applied on 3 parallel preparations of 
suppositories. The average recovery was 92.6±2.8%. Due to the fact that during longer US 
treatment the transfer medium underwent warming, longer agitation times were not applied. 
The ineffectiveness of the individual effects described in sections 4.2.2.1, 4.2.2.2 and 4.2.2.3 
led to the straightforward idea to study the combined effects of sodium chloride, sodium 
hydroxide and US treatment simultaneously. 
4.2.2.4. Combined effect of sodium chloride and sodium hydroxide on drug recovery 
The combination of sodium chloride and sodium hydroxide was tested together with an 
additional 30 min US treatment. Constant, 100 mM sodium chloride and 0, 10, 20 or 40 mM 
sodium hydroxide were applied. The recovery results were favourable at 20 and 40 mM 
sodium hydroxide concentrations: 95.7% and 98.0%, respectively. Figure 12 clearly reveals 
the correlation between the sodium hydroxide concentration and the recovery of the API when 
sodium chloride was present in the sample. The application of 100 mM sodium chloride and 
40 mM sodium hydroxide was suggested. 
This sample preparation method was also tested on paracetamol. Samples were prepared 
by the combined sodium chloride and sodium hydroxide addition method described in the 
previous paragraph. The suppository was modelled by combining the blank hard fat 
suppository, Tween 20 and Tween 60 in the appropriate proportion and exactly weighed 100.0 
mg of paracetamol. The sodium hydroxide concentration was set to 0, 10, 20 or 40 mM 
during the experiment. The recoveries determined by HPLC analysis are presented in 
Figure 12, plot d. In the case of paracetamol, 40 mM sodium hydroxide was required to 
liberate the API entirely. The average recovery was found to be 98.4%. 
The covariance values for plots c and d in Figure 12 reveal a strong positive 
relationship between the increase of the hydroxide concentration and the change in the 
recovery. These values are significantly higher than those determined for plots a and b in 
Figure 12.  
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4.2.2.5. Extension of sample preparation method developed in section 4.2.1 
On the basis of the results described in subsection 4.2.2.4, the sample preparation 
method shown in section 4.2.1 needed to be amended with the following extra step. 
2 ml of 1 M NaOH and 1 ml of 5 M NaCl solution were added to the initial 15 ml of 
solvent mixture and the solution was sonicated for 30 min. After this, the sample preparation 
procedure remained similar to that described in section 4.2.1. The scheme of micelle breaking 
can be seen in Figure 13. 
In order to find evidence of micelle formation in the sample solution of W35TT, the 
determination of CMC for both surfactants became necessary. The results of these studies are 
presented in the following section. 
 
 
Figure 13 Theoretical figure of micelle-breaking mechanism 
4.2.3. CMC determination: CMCs of TWEEN 20 and TWEEN 60 
The concentration range for the combined surfactants was determined from the data for 
the initially characterized individual Tween 60 and Tween 20. The highest concentration in 
the series was always 0.5 mM, which corresponds to that of both surfactants in the sample 
solution in the analytical method for suppositories containing W35TT. 
The absorbances of the series of solutions were determined at 550 nm at ambient 
temperature. This wavelength was chosen on the basis of preliminary experiments. A solution 
was prepared in which the surfactant concentration corresponded to the composition of the 
sample solution and a spectrum was acquired between 200 and 600 nm. In the spectrum, the 
wavelength for the study was chosen from a plateau region where the absorption was 
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independent of the wavelength. This indicated that the increase in absorbance is due to 
scattering rather than absorption. The absorbances obtained in this way were plotted against 
surfactant concentrations. The linear regions of the plots were fitted by straight lines and the 
intersection of the straight lines gave the concentration of the CMC. The CMC can be 
identified as the breakpoint of the absorbance vs. concentration curve [69, 106]. 
Table 6 Surfactant concentration ranges of CMC determination 
 Concentration/mM 
Tween 60 0 0.03 0.04 0.05 0.06 0.08 0.09 0.1 0.2 0.3 0.5      
Tween 20 0 0.04 0.05 0.06 0.07 0.08 0.1 0.3 0.5        
Tween 20 & 60 0 0.001 0.005 0.01 0.02 0.03 0.04 0.05 0.06 0.08 0.1 0.3 0.5    
Tween 20 & 60 
with NaOH 
0 0.001 0.005 0.01 0.02 0.03 0.04 0.05 0.06 0.08 0.1 0.3 0.5 0.7 0.8 0.9 
The CMCs of Tween 20 and Tween 60 were determined in the applied solvent mixture: 
MeOH : water (50:50 V/V) in the presence of hard fat by measuring the turbidity of solutions 
with different surfactant concentrations at 550 nm. Four series of solutions were prepared 
with a constant amount of hard fat and increasing concentrations of the two surfactants, either 
separately or together, and together in the presence of NaOH. The concentrations used are 
listed in Table 6. 
Table 7 Calculation of CMCs from the data of fitted straight lines 
 Slope SD Intercept SD Intersect/mM 
Tween 20 
0.4 ± 0.110 0.24 ± 0.033 
0.084 
2.8 ± 0.485 0.04 ± 0.027 
Tween 60 
0.52 ± 0.039 0.12 ± 0.011 
0.061 
4.1 ± 1.022 -0.096 ± 0.047 
Tween 20 & 
Tween 60 
2.1 ± 0.163 0.75 ± 0.040 
0.040 
12.6 ± 2.083 0.34 ± 0.032 
Tweens 20 & 60 
with salt and base 
0.07 ± 0.011 1.99 ± 0.199 
0.324 
0.529 ± 0.008 -0.09 ± 0.037 
Turbidity was plotted against surfactant concentration. Straight lines were fitted to each 
series of points. The parameters of the fitted straight lines and their intersects are presented in 
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Table 7. In MeOH : water (50:50, V/V) as solven,t the CMCs of Tween 20, Tween 60 and 
their mixture were 0.084 mM, 0.061 mM, and 0.040 mM, respectively. 
These results are in good agreement with the trends reported in previous studies. The 
slight differences from the literature data (Table 1) can be attributed to the different 
measurement techniques and the different solvents [59, 62]. The solvent in this case, an 
equivolume mixture of water and MeOH, could increase the CMC. Short-chain alcohols such 
as MeOH or ethanol are known to decrease the hydration of the ethylene oxide chains of non-
ionic surfactants, so the observed trend in the CMC increase is in good agreement with this 
explanation [107]. The tendencies earlier found for different Tween substances can be 
observed in our results too: the CMC of Tween 20 is higher than that of Tween 60. Moreover, 
the two surfactants together give a significantly lower CMC, which is also characteristic [58]. 
It is obvious that the applied surfactant concentration in the suppository base is well above the 
determined CMC, which explains the micelle formation and the decreased recovery of drug as 
compared with the “pure” hard fat. Although the application of surfactants in the suppository 
base has a beneficial effect on the formulation properties of the material and on the drug 
release in the body, the amounts of surfactants must be optimized to avoid the analytical 
pitfall of failing the recovery study. Too high a surfactant concentration will always pose a 
potential risk of analytical error. 
 
Figure 14 Turbidimetric plots for determination of CMCs of Tween 20 (▪), Tween 60 (▪), Tween 20 & 60 
(▪) and Tweens 20 & 60 with salt and base (▪) 
The complex sample preparation method, which was tested with two different model 
compounds, is rapid and effective in the case of suppository bases containing surfactants to 
enhance the liberation of the encapsulated drugs. The success of the development can be 
4. RESULTS – PART II. 
37 
explained through the micelles losing their colloidal stability due to the loss of electrostatic 
interactions, which is caused by the addition of electrolytes. The mechanism is similar to that 
in formulations with targeted drug release. The initial hypothesis was proven by determining 
the CMC of Tween 20 and Tween 60 in a medium where the final sodium chloride 
concentration was 100 mM and the sodium hydroxide concentration was 40 mM. The results 
can be seen in Figure 14. The CMC of the combined surfactants is about 5 times higher in the 
presence of salt and base than in their absence. The applied salt and base concentrations 
combined with the US treatment was sufficient to raise the CMC of the system so that the 
surfactants within the suppository could not assemble into micelles entrapping part of the API. 
4.2.4. Stability verification of the drugs by NMR spectroscopy during sample 
preparation 
The stability of the prepared samples was verified to make sure that the applied sample 
preparation method did not cause any degradation or decomposition of the active substance 
(AMFZ or paracetamol) and that its structure remained unchanged throughout the experiment. 
The measurements were carried out at 25 °C. 
The analytical sequence for both model compounds incorporated the measurement of a 
reference solution, which contained the appropriate compound in the solvent used during the 
chromatographic sample preparation, and the sample solution itself. The method of sample 
preparation for the HPLC measurements had to be altered slightly as the NMR studies 
required higher concentrations of the active substances. A 5-fold amount of AMFZ or 
paracetamol (500 mg) was therefore dissolved in the appropriate solvent described in section 
4.2.1 to 50 ml in the case of the reference solutions. The sample solution was prepared 
similarly to the reference solution, except that 1 W35TT blank suppository was dissolved in 
the solvent together with 1 ml of 1 M sodium hydroxide and 1 ml of 5 M sodium chloride 
solution before making the solution up to volume. For the paracetamol measurements, 500 mg 
of substance was dissolved for the reference solution in 50 ml of solvent described in section 
4.2.1. The solution modelling the sample was prepared by dissolving 500 mg of paracetamol, 
and placing 1 blank W35TT suppository in the first 15 ml of solvent. Micelle demulsion was 
achieved according to subsection 4.2.2.5, except for the last dilution step. 10 V/V% of D2O 
was added to each sample before the NMR measurements. 
In the assigned spectra of paracetamol, the signals of the OH and NH protons are not 
visible due to the fast exchange with water. It is clearly visible in the paracetamol sample 
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spectrum that, due to the deprotonation of the OH and NH groups with the increase of pH, the 
chemical shift of the aromatic protons decreases by 0.2 ppm. In the case of AMFZ, no 
deprotonation takes place, and thus there is no change in the chemical shifts. 
The overlaid spectra showed no significant difference, i.e. no new peaks were detected, 
which confirmed that the samples remained intact during the sample preparation (Figure 15). 
 
Figure 15 1H NMR spectra of aminophenazone and paracetamol standards and samples. The signals 
marked with letters prove that no decomposition takes place in the sample solution treated with strong 
base. Peaks a and b of paracetamol are shifted to the right by 0.2 ppm due to the deprotonation of the OH 
and NH groups in the alkaline medium 
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4.2.5. Dissolution tests of hard fat and W35TT suppositories 
Dissolution tests were carried out in a Hanson SR8+ dissolution tester equipped with a 
basket apparatus. Commercially available suppositories (prepared for children) containing 
aminophenazone and either hard fat or W35TT were tested. The dissolution medium, 
potassium dihydrogenphosphate buffer (pH 7.5; 0.05 M), was thermostated to 37 °C. The 
agitation speed was 50 rpm. Samples were collected at 5, 10, 15, 30, 45, 60 and 120 min and 
tested by HPLC with the system described in section 2.2.3.  
 
Figure 16 Dissolution profiles of AMFZ containing hard fat (•) and W35TT (♦) suppositories 
Six dosage units were tested from both hard fat and W35TT-containing suppositories 
according to the parameters described in section 2.2.7. It can be seen in Figure 16 that 
dissolution from solid fat-based suppositories is slower in the time range critical for the in 
vivo effect, and up to 120 min only 70% of the drug is released. W35TT-based suppositories 
demonstrated saturation from 60 min (88.9±10.9%). On the other hand, it should be noted that 
during these experiments the volume of the dissolution medium was 900 ml, where the 
concentration of Tween 20 was 0.0244 mM and that of Tween 60 was 0.0228 mM, which was 
significantly lower than in the case of our analytical samples. Application of such large 
volumes for sample preparation to avoid micelle formation is not recommended in routine 
laboratories. Furthermore, it is worth consideration that the dissolution rate in large volumes 
is favourably influenced by surfactants because their concentration falls below their CMC, but 
this certainly cannot model the physiological conditions, where the volume of rectal fluid is 
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only 2-3 ml. In such a small volume, the surfactant concentration will be definitely higher 
than those in our analytical samples and will fall above the CMC in every case. If a 2.5 ml 
rectal fluid volume is hypothesized, the  concentration of Tween 20 will be 9.76 mM and that 
of Tween 60 will be 9.12 mM, accounting for an even higher extent of micelle formation. 
4.2.6. Extension of the validation study with matrix-dependent performance 
characteristics 
Precision/ Repeatability 
Repeatability was checked on 6 individual AMFZ or paracetamol suppositories prepared 
according to the developed methods described in sections 4.2.1 and 4.2.2.5. In the case of 
adeps solidus as vehicle, 1 of the 6 replicate results exceeded the 125% limit, and this result 
was omitted from the calculation of the RSD% on the basis of our result that there is no 
carryover between the injections and the fact that active substance was not added to the 
solution. RSD% proved to be 1.4%, which can be considered acceptable when it is taken into 
account that not composite samples of multiple dosage units, but rather unique dosage units 
were used for each sample preparation. The massa macrogoli-based suppositories gave an 
RSD% of 2.1% and the AMFZ W35TT samples had an RSD% of 1.5%, which are also 
acceptable. The other model system (paracetamol W35TT) results are similarlye acceptable, 
because the RSD% is 4.4%. 
Precision/ Intermediate precision 
The same analysis procedure was carried out by another analyst on another day, using a 
freshly prepared mobile phase.  
 %1002
XX
XX
  difference Relative
Day21Day
Day21Day
⋅⋅
+
−
=  (5) 
The results for the adeps solidus-based samples of AMFZ were an RSD% of 1.2% and a 
relative difference of 1.3% between the averages of the repeatability (Day 1) and intermediate 
precision (Day 2) results compared to the mean of the average values measured for each. Both 
results can be accepted according to the principles of general pharmaceutical analytical 
practice. For the massa macrogoli-based samples of AMFZ, the RSD% of the individual 
results was 2.5%, while the relative difference between the repeatability and intermediate 
precision was 3.7%. The samples of the third vehicle, W35TT with AMFZ, gave an RSD% of 
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1.7%, while the relative difference was found to be 5.5%. These values for W35TT samples 
of paracetamol were an RSD% of 4.9% and a relative difference of 2.9%. All four results 
were in accordance with the appropriate guidelines, and were therefore considered acceptable. 
Accuracy 
The accuracy of the AMFZ method was studied between 50% and 450% of the nominal 
content of the suppositories, i.e. 100 mg, except for W35TT, which was studied between 50% 
and 300%. The results are shown in Table S-4. Although all of the average values fell 
between 95% and 105%, it should be mentioned that in the cases of adeps solidus and W35TT 
most of the averages were below 100%, while in the case of massa macrogoli they were above 
100%. This may raise a warning flag, but there was no trend within the results that could be 
correlated with the increasing concentration of the sample groups. 
The accuracy of the paracetamol method with respect to the W35TT base was studied at 
50%, 100%, 150% and 200% concentration levels with three parallel samples. The results fell in 
the range 100.9-103.2%, which is acceptable. The results are shown in Table S-5. 
Specificity 
When the procedure was carried out with blank suppositories (containing no active 
substance), no peak was detected at the retention times of AMFZ or paracetamol. It can be 
stated that there are no excipients in either vehicle that interfere with the determination of 
AMFZ or paracetamol. 
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4.3. Part III. Quantitative analysis of magistrally produced suppositories 
In this section, an investigation of samples prepared in pharmacies is reported, with 
special emphasis on the homogeneity and the total API content of the batches. The 
circumstances of the preparation of the suppositories were known in all cases and are 
presented. 
4.3.1. Comparison of the assay results obtained with cerimetric titration and HPLC  
Two analytical methods were first compared by measuring 6 samples each from the 
same factory-produced batch, and the individual assays of the suppositories were carried out 
by either the volumetric titration (see section 3.2.2) or the chromatographic technique. 
Samples of extemporaneously prepared suppositories for HPLC analysis were prepared 
according to the flow chart in Figure 17. 
All of the final results (the averages of the 3 replicates in the case of the titrimetric 
method, and the assay value in the case of the chromatographic determination) fell within the 
range 95-105%, which conforms to the strictest requirements of the EP. The individual 
content data are presented in Table 8. 
Table 8 Assay results on factory-produced suppository samples, measured by titrimetry or HPLC 
Sample 
Cerimetric titration HPLC assay 
Replicates % Content % Content % 
1 101.6 107.2 103.5 104.1 103.9 
2 98.9 99.3 97.5 98.5 104.9 
3 106.3 100.7 100.3 102.4 102.8 
4 96.1 100.7 97.1 98.0 102.3 
5 100.9 110.4 102.1 104.5 103.9 
6 103.6 104.0 104.7 104.1 104.6 
Mean - - - 101.9 103.7 
SD - - - 2.93 1.01 
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Figure 17 The flow chart of the sample preparation procedure 
It should be noted that the volumetric results exhibit a larger standard deviation than 
that of the chromatographic results, but the preparation of the sample for titrimetry (replicate 
samples are prepared from the molten suppository) involves a higher level of uncertainty, and 
this can therefore be considered acceptable. Comparison of the two methods reveals that both 
can be used for the analysis of suppositories containing AMFZ. 
4.3.2. Dosage uniformity study of magistrally produced suppositories 
We additionally studied paediatric suppositories with the composition described in 
section 3.1. All samples were from different Hungarian public pharmacies, and each sample 
consisted of 10 individual suppositories. The manufacturing technology of each of the 
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samples was known to us; the pharmacists committed intentional technological errors during 
the preparation of the suppositories. Samples Ph1-Ph9 were measured with the HPLC 
technique described in subsection 4.1.2.2, while samples Ph10-Ph15 were tested for dosage 
uniformity with the titrimetric method presented in section 3.2.2. Ph in the sample identifier 
stands for pharmacy. All of the findings were compared (see Figure 18 and Table 9) on the 
basis of the results given in section 4.3.1. It can be stated that 2 samples conformed to the 
specifications of EP 7.8, i.e. the individual assay values fell within the range 85-115% at level 
1, and 1 further sample would probably conform to the level 2 specification of 75-125%. For 
the remaining samples, generally either lower individual assay results or (in 2 samples) 
significant inhomogeneity was found. 
 
Figure 18 Mean API contents for the samples, with the standard deviations. An API content in the 
interval 85-115% is satisfactory. Samples Ph1-Ph9: measured by HPLC; samples Ph10-Ph15 measured by 
cerimetric titration 
4.3.3. Effects of f on the assay results 
The possible consequences of the most common errors can be illustrated on a theoretical 
example. If the pharmacist produces suppositories on the basis of the following parameters: 
E = 1.7 g f = 0.78 and s = 0.1 g, then, according to Equation 1, Tm = 15.22 g for 10 
suppositories. If f is not applied, but only the weight of the API is subtracted from the value of 
E, then we heve Tm = 16.0, which will result in an assay 4.6% lower than the required value. 
If this error is superimposed with the one when the calculated moulding excess is taken solely 
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from the suppository base, by taking the required base for 12 dosage units instead of 10, the 
concentration of 1 suppository is diluted even further, to 80.3% of the intended theoretical 
value. Such errors are visible in case of samples Ph3, Ph8, Ph11 or Ph12.  
4.3.4. Effects of stirring on the homogeneity and total assay of the samples 
The suppository mass can be homogenized well by choosing an appropriate rate of 
manual stirring or machine-based mixing. Stirring during the moulding process can help 
avoid sedimentation of the active substance in the container. Too slow stirring is not effective, 
but too fast stirring may also lead to errors: air bubbles are formed in the mass, which will 
decrease the weight of the suppositories, foam can be formed from surfactant-containing 
bases, or shearing forces may appear, which decrease the viscosity of the suppository mass by 
rheodestruction, causing the rapid sedimentation of the active substance. The ideal machine 
stirring speed for fat-based suppositories is 150 rpm.  
Table 9 Average assay results on the samples and standard deviations in the homogeneity study 
Sample Ph1 Ph2 Ph3 Ph4 Ph5 Ph6 Ph7 Ph8 Ph9 Ph10 Ph11 Ph12 Ph13 Ph14 Ph15 
Average % 87.7 56.1 75.6 74.8 85.8 84.7 86.9 76.2 49.5 93.7 75.5 70.4 82.9 54.9 78.6 
SD 4.8 3.6 3.6 11.1 52.8 11.6 3.0 7.8 7.0 10.2 8.0 7.4 79.7 5.5 14.3 
The results demonstrate that the stirring technique of the preparing pharmacist before 
and during the moulding procedure was appropriate, with the exception of a small number of 
serious cases. Those samples can be considered homogeneous which gave SD ≤ 10 with 
respect to the individual suppository assays. A larger deviation can originate from the lack of 
stirring during the moulding, as may be seen for samples Ph4, Ph6 and Ph15. Extremely large 
deviations result when both thorough homogenization and stirring during the moulding 
process are omitted, which may be observed for samples Ph5 and Ph13. If f is not applied and 
the suppository base is applied in excess amount, the assays of the samples will fall below the 
lower limit of acceptance. If the molten mass is not stirred during moulding, the decrease in 
the active substance content becomes more serious as the suspended material is sedimented, 
and the mould will contain an active substance-depleted mixture. Such samples were Ph2, 
Ph9 and Ph14. 
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5. Final conclusions 
5.1. Conclusions of Part I 
The presented results clearly demonstrate that the most challenging part of the 
development was to find an appropriate stationary phase on which all 3 compounds can be 
separated with good peak symmetry and resolution. The Hypersil ODS stationary phase 
proved to be too retentive for papaverine and it was obvious during the development that good 
peak shape cannot be achieved. The application of a stationary phase equivalence chart led us 
to Zorbax SB-C18 and Luna C18 stationary phases, which were more hydrophobic and more 
selective according to the chart data. The increased hydrophobicity of the stationary phase 
made it necessary to reduce the final organic modifier content of the gradient. In this way, all 
three compounds eluted within 10 min and were separated well on both stationary phases. 
Another problem was the low solubility of ASA in water. In organic solvents such as MeOH 
or ACN it is freely soluble, but a higher organic content of the mobile phase would have 
caused the too early elution of paracetamol (within the void peak) which is unacceptable. A 
too low organic content, on the other hand, led to the ASA precipitating and clogging the 
tubing and the column. In the final method, a balance was successfully found between 
retention and solubility by applying 7% ACN content in the initial phase of the gradient. The 
peak symmetry and selectivity were found to be better on the Zorbax SB-C18 phase. This 
column was therefore chosen for the final method and the validation steps were carried out 
with this phase. An elevated column temperature made it possible to develop a rapid and 
efficient method with rather low back-pressure (a maximum of about 100 bar during the runs), 
which ensures a longer column lifetime. The method validation was carried out according to 
current ICH guidelines. All the results satisfied the guideline requirements. 
5.2. Conclusions of Part II 
The data presented in this section revealed that a rapid, efficient and robust sample 
preparation procedure and HPLC method were successfully developed and fully validated for 
the routine quality control of the dosage units of suppositories containing AMFZ as active 
substance in various vehicles as supporting materials. The method is simple and sufficiently 
general to be conveniently used for the regular quality control of AMFZ suppositories 
formulated through the use of different suppository bases. 
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An adequate sample preparation method was developed for Tween 20 and Tween 
60-containing hard fat-based suppositories. We proved that micelles are formed in the sample 
solution and successfully destabilized them by applying 100 mM sodium chloride and 40 mM 
sodium hydroxide and 30 min US treatment, which made the complete release of two 
physico-chemically different APIs possible. Provided that there are appropriate 
chromatographic methods at hand, the developed sample preparation method could be utilized 
for the determination of other drug molecules from surfactant-containing suppositories too. 
This problem raises the question of how micelle formation influences drug release during 
therapeutic application. As the problem appeared during the melting of the suppository for 
analytical sample preparation, the question arises of whether this phenomenon would cause 
homogeneity problems at surfactant concentrations higher than the CMC in suppositories 
produced by industrial technology, which is based mainly on moulding techniques for large 
quantities. 
5.3. Conclusions of Part III 
The results for paediatric suppositories produced extemporaneously under predefined 
conditions in Hungarian independent pharmacies revealed that serious errors may arise if the 
rules used in the pharmaceutical technology for preparing such suppositories are not strictly 
adhered to, and the assay results on the individual dosage units may be affected. On the other 
hand, suppositories prepared with strict adherence to the correct manufacturing practices 
conform to the specifications described in EP 7.8. Since extemporaneously prepared 
suppository preparations are frequently compounded and supplied in central European clinical 
pharmaceutical practice because of the low costs involved, I would encourage the use of and 
the inclusion of the f values for the most common APIs and for the most common suppository 
bases into the European or national pharmacopoeias. To my knowledge, the paucity of this 
information prohibits the preparation of the “right” dose for the “right” patient and may even 
cause harm. Calibration of the mould and the determination of the f value for these basic 
common suppository bases can be accomplished very simply. 
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Summary 
1.  A HPLC method was developed and validated for the simultaneous assay of an oral 
powder dosage form containing 3 APIs. 
 1.1. The pH of the mobile phase was determined with chromatographic prediction 
software on the basis of paracetamol, ASA and papaverine log D vs. pH functions. pH 
3.4 ±0.05 was found to be a reasonable compromise for the pH of the aqueous phase. 
 1.2. Appropriate organic-aqueous ratio and gradient profile were determined in order to 
achieve satisfactory retention and peak shape. 
 1.3. Different stationary phases were compared for the separation of compounds with 
different polarities. Of the 3 stationary phases tested (ODS Hypersil, Luna C18, 
Zorbax SB-C18), Zorbax SB-C18 proved to be the most suitable on the basis of the 
separation parameters calculated from the chromatograms. 
 1.4. The developed method was validated by testing linearity, precision (repeatability and 
intermediate precision), accuracy, specificity and robustness. The method met all the 
acceptance criteria set up before validation. 
2. A HPLC method was developed and validated for the assay of AMFZ and paracetamol. 
 2.1. A RP-HPLC assay method was developed for AMFZ. 
 2.2. A RP-HPLC assay method was developed for paracetamol. 
 2.3. Both methods were validated by testing linearity, precision (repeatability and 
intermediate precision), accuracy, specificity and robustness. Accuracy was tested in 
an extended range (up to 450% of the labelled claim) in the case of AMFZ, and 
specificity was also tested with respect to the solvent and matrix components. Both 
methods met all the acceptance criteria set up before validation. 
3.  A sample preparation procedure was elaborated for the analysis of suppositories prepared 
from any of the possible 3 different suppository bases. 
 3.1. API recovery from lipophilic hard fat suppository base with a freezing technique. 
 3.2. API recovery from hydrophilic massa macrogoli suppository with dissolution. 
 3.3. API recovery from W35TT suppository base with micelle breaking. The effects of 
solvent pH, salt concentration and length of US treatment on the recovery efficiency 
were studied independently and simultaneously. The most effective conditions were 
found to be the combination of 100 mM NaCl, 40 mM NaOH and 30 min US treatment. 
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 3.4. Turbidimetric CMC determination of the surfactant components of W35TT 
suppository base. Tween 20, Tween 60 and Tween 20+60 CMC were measured in 
MeOH-water as solvent. Tween 20+60 CMC was measured in MeOH-water and under 
the most effective conditions described in section 3.3. 
 3.5. In a comparative dissolution study of adeps solidus and W35TT-based suppositories, 
dissolution samples were analysed with the HPLC method developed in section 2.1. 
Dissolution was found to be faster from the W35TT matrix in 900 ml of dissolution 
medium (pH=7.5). The beneficial effect of surfactants observed under in vitro 
conditions may decrease when an in vivo available volume of rectal fluid of about 2 ml 
is considered. In this case, the concentration of applied surfactants will be higher than 
the CMC. Thus, formation of micelles cannot be avoided, which may decrease the 
bioavailability of the administered drug. The application of less surfactant is therefore 
suggested. 
 3.6. The structural stability of AMFZ and paracetamol was studied with NMR 
spectroscopy under the conditions applied for micelle breaking. (100 mM NaCl, 
40 mM NaOH and 30 min US). No change was observed between the NMR spectra of 
the reference and test solutions, which proved that the 2 APIs did not suffer 
degradation during US and basic treatment. 
4.  Comparative analysis was performed of magistrally produced suppositories (HPLC assay) 
with identification of manufacturing errors. 
 4.1. The assay results obtained with cerimetric titration and RP-HPLC were compared. 
Classical titration and HPLC assay can be applied equivalently for the analysis of 
AMFZ. 
 4.2. In a dosage uniformity study of magistrally produced suppositories, sample batches of 
10 AMFZ-containing suppositories prepared by and purchased from 15 Hungarian 
pharmacies were tested. 
 4.3. The effects of f on the assay results were identified. It is strongly suggested that the f 
values for the most common APIs should be determined, and applied in everyday 
pharmaceutical practice. 
 4.4. The effects of stirring on the homogeneity and total assay of the suppository samples 
indicated that the lack of stirring may lead to decreased homogeneity and API content, 
depending on the phase in which stirring was omitted. 
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Table S-1 Results of accuracy studies 
Level  Paracetamol % ASA % Papaverine % 
  Rep. Mean RSD Rep. Mean RSD Rep Mean RSD 
70% 
1. 103.0 
102.5 0.45 
100.8 
100.1 0.61 
98.4 
98.1 0.26 2. 102.1 99.8 97.9 
3. 102.3 99.7 98.2 
100% 
1. 101.4 
101.9 0.43 
98.3 
98.5 0.17 
98.2 
98.7 0.47 2. 102.3 98.7 98.9 
3. 102.1 98.5 99.0 
130% 
1. 100.7 
101.7 0.94 
97.0 
97.6 0.59 
95.8 
96.8 0.90 2. 102.5 98.1 97.4 
3. 102.1 97.7 97.1 
 
  
Table S-2 Results of method robustness tests 
Condition changed 
 Paracetamol ASA Papaverine 
 tR/min N 
Symmetry 
factor 
tR/min N 
Symmetry 
factor 
tR/min N 
Symmetry 
factor 
Column 
temperature/°C  
55 2.660 6380 1.261 6.324 69377 1.445 7.122 50747 1.597 
60 2.527 5540 1.237 6.213 69445 1.460 7.160 53197 1.588 
65 2.358 5600 1.264 6.032 81057 1.423 6.992 60963 1.542 
Buffer pH 
3.23 2.531 5843 1.249 6.308 68186 1.476 6.933 53433 1.629 
3.43 2.527 5540 1.237 6.213 69445 1.460 7.160 53197 1.588 
3.63 2.516 5690 1.245 6.072 75013 1.412 7.252 52516 1.563 
Flow rate/(ml/min) 
1.4 2.695 5521 1.242 6.453 68816 1.437 7.459 51720 1.604 
1.5 2.527 5540 1.237 6.213 69445 1.460 7.160 53197 1.588 
1.6 2.357 5346 1.265 6.000 70952 1.449 6.900 53720 1.595 
Aqueous : organic ratio 
5% 3.030 6408 1.210 6.324 77103 1.418 7.132 54830 1.583 
7% 2.527 5540 1.237 6.213 69445 1.460 7.160 53197 1.588 
9% 2.122 5865 1.319 5.986 69115 1.476 6.947 54415 1.567 
23% 2.516 6052 1.270 6.399 65585 1.404 7.714 45410 1.613 
25% 2.527 5540 1.237 6.213 69445 1.460 7.160 53197 1.588 
27% 2.502 6152 1.252 5.998 78520 1.443 6.618 63169 1.559 
 
  
Table S-3 Results of robustness studies. The second line of every condition changed refers to the nominal 
value of the parameter 
Condition  
changed 
AMFZ method Paracetamol method 
 tR/min N 
Symmetry 
factor 
 tR/min N 
Symmetry 
factor 
Aqueous : organic  
ratio 
45:55 2.088 3973 1.535 95:5 4.309 2512 0.911 
40:60 1.761 4074 1.434 90:10 2.400 2887 1.148 
35:65 1.616 4512 1.460 85:15 1.803 3746 1.215 
Buffer pH 
5.00±0.05 1.837 3747 1.602 5.80±0.05 2.391 2948 1.146 
5.50±0.05 1.761 4074 1.434 6.30±0.05 2.400 2887 1.148 
6.00±0.05 1.846 4441 1.346 6.80±0.05 2.421 2906 1.150 
Flow rate 
(ml/min) 
1.3 2.021 4346 1.432 1.0 3.575 3458 1.132 
1.5 1.761 4047 1.434 1.5 2.400 2887 1.148 
1.7 1.676 4117 1.405 2.0 1.799 2495 1.175 
Column 
temperature/°C 
25 1.785 3890 1.433 25 2.514 3134 1.168 
30 1.761 4074 1.434 30 2.400 2887 1.148 
35 1.751 4340 1.408 35 2.308 2873 1.119 
 
  
Table S-4 Results of AMFZ accuracy studies 
Level 
Adeps solidus Massa macrogoli W35TT 
Replicates Mean RSD% Replicates Mean RSD% Replicates Mean RSD% 
50% 
1. 98.7% 
99.4% 0.63% 
104.10% 
102.5% 1.56% 
102.3% 
98.8% 3.24% 2. 99.9% 100.90% 96.0% 
3. 99.6% 102.40% 98.2% 
100% 
1. 99.5% 
100.3% 0.75% 
97.40% 
99.7% 1.99% 
97.7% 
99.5% 2.71% 2. 100.3% 100.50% 98.2% 
3. 101.0% 101.10% 102.6% 
150% 
1. 96.0% 
95.3% 1.36% 
104.60% 
104.9% 0.42% 
101.3% 
99.7% 2.05% 2. 93.8% 105.40% 100.4% 
3. 96.1% 104.70% 97.4% 
300% 
1. 96.2% 
95.5% 0.87% 
104.60% 
102.7% 2.43% 
100.1% 
99.2% 1.84% 2. 95.8% 103.70% 97.1% 
3. 94.6% 99.90% 100.4% 
450% 
1. 96.3% 
96.5% 0.55% 
102.80% 
102.5% 1.49% 
- 
- - 2. 96.1% 103.80% - 
3. 97.1% 100.80% - 
 
  
Table S-5 Results of accuracy measurement of paracetamol in W35TT 
Level 
Replicates 
recovery (%) 
Mean (%) RSD% 
50% 
1. 95.4 
101.1 6.8 2. 108.7 
3. 99.1 
100% 
1. 96.9 
99.2 3.3 2. 97.8 
3. 103.0 
150% 
1. 102.1 
103.2 1.1 2. 103.2 
3. 104.3 
200% 
1. 105.0 
100.9 4.9 2. 102.2 
3. 95.4 
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Rectal  drug  delivery  is currently  at  the  focus  of attention.  Surfactants promote  drug  release from the
suppository  bases and  enhance  the  formulation  properties.  The  aim  of  our work was to  develop a sample
preparation  method  for HPLC  analysis  for a suppository  base  containing  95% hard fat,  2.5% Tween  20
and  2.5% Tween 60. A  conventional  sample preparation method  did not  provide  successful results as  the
recovery  of the drug  failed  to  fulﬁl  the  validation  criterion  95–105%.  This  was caused  by the non-ionic
surfactants  in the  suppository  base  incorporating some of the drug,  preventing  its release. As guidance
for the formulation  from an analytical  aspect,  we  suggest a well  deﬁned surfactant content based on
the  turbidimetric  determination  of  the  CMC  (critical  micelle  formation  concentration)  in  the  applied
methanol–water  solvent.  Our  CMC  data correlate  well with  the results of  previous studies. As  regards
the  sample  preparation procedure, a study was  performed  of the effects of  ionic  strength and pH on  the
drug  recovery  with the avoidance  of degradation  of the  drug during  the  procedure.  Aminophenazone
and  paracetamol  were  used as model drugs. The optimum  conditions  for  drug  release  from  the  molten
suppository  base  were  found  to be 100  mM NaCl, 20–40 mM NaOH  and  a 30 min ultrasonic  treatment of
the  ﬁnal  sample  solution.  As these  conditions  could  cause  the degradation  of the  drugs  in  the solution,
this  was followed by  NMR spectroscopy, and  the results indicated  that  degradation  did not  take  place.
The  determined  CMCs were  0.08  mM for  Tween  20, 0.06 mM for Tween  60  and  0.04  mM for a combined
Tween  20, Tween 60 system.
© 2013 Elsevier B.V. All rights reserved.
1. Introduction
The use of suppositories as a dosage form has once again
come into the foreground. Besides traditional antifebrile suppos-
itories, suppositories containing probiotics are becoming more
widespread. Ulcerative colitis and colorectal carcinoma are cur-
rently being diagnosed in rising numbers among children in  Great
Britain, and rectal drug administration is increasingly and more fre-
quently resorted to in the pre- and postoperative therapy of such
diseases [1–7].
Numerous studies that have focused on  the liberation of drugs
from suppositories containing surfactants from the aspect of phar-
maceutical technology have clearly revealed that it  is beneﬁcial for
a suppository base to have high hydroxyl group content. The usage
of non-ionic surfactants is now suggested, but in lower amounts
than those used in older recipes, which generally means lower than
3%, and preferably around 1% [8].  A high surfactant concentration
may  lead to the formation of micelles, which incorporate some of
∗ Corresponding author. Tel.: +36 62545925; fax: +36 62545806.
E-mail address: gerda.szakonyi@pharm.u-szeged.hu (G. Szakonyi).
the API, impeding its release [9].  According to Ghorab et al. [10] opti-
mum  amount of  Tween 60 is 5%, higher proportion than that up to
10% had lower effect on the release rate. Above 10% the release rate
is decreased due to micelle formation. Surfactants not only enhance
release of the drug form the suppository base but increase the per-
meability of the tissues surrounding the rectal lumen. Non-ionic
surfactant Tween 20 showed outstanding effectiveness used in 5%
amount combined with lipophilic vehicles [11].
One of the most characteristic properties of a surfactant is its
CMC. In a speciﬁc solvent system, this is the concentration above
which individual surfactant molecules spontaneously aggregate
and form micelles through secondary interactions. Several meth-
ods are available for the determination of CMC. The most widely
used techniques are the measurement of surface tension, conduc-
tance in the case of ionic surfactants, UV–vis spectrophotometry,
NIR spectroscopy, turbidimetry and densitometry [12,13]. As the
suppository base studied in the present work contained Tween
20 and Tween 60, in Table 1 we  list the CMCs of these materials
determined with different methods in previous studies.
In the present work, we focus on the role of non-ionic surfac-
tants through the analysis of suppositories. In the case of  generics,
besides the technological formulation, the development of  analyt-
ical methods is needed to acquire the data required for ofﬁcial
0731-7085/$ – see front matter ©  2013 Elsevier B.V. All rights reserved.
http://dx.doi.org/10.1016/j.jpba.2013.04.039
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Table 1
CMCs of Tween 20 and Tween 60.
Reference Method Temperature Medium
H2O D2O Spec.a
Tween 20
[14] Surface tension RT 0.0804 – –
[15] NIR RT 0.08 0.12 70
[16] Surface tension RT 0.0488 – –
[17] Densitometry 24.88 ◦C 0.097 – –
[18] Surface tension RT 0.059 – –
[19] Spectrophotometry of iodine absorbance RT 0.055 – –
Shift in  max RT 0.0557 – –
Surface tension RT 0.0488 – –
[20] Surface tension RT 0.048 – –
[21] Dye micellization RT 0.042 – –
Surface tension RT 0.011 – –
Tween 60
[17] Densitometry 24.88 ◦C 0.068 – –
[19] Spectrophotometry of iodine absorbance RT 0.0209 – –
Shift in  max RT 0.0196 – –
Surface tension RT 0.0206 – –
[20] Surface tension RT 0.021 – –
[21] Dye micellization RT 0.022 – –
Surface tension RT 0.0055 – –
a 1-Ethyl-3-methylimidazolium bis(triﬂuoromethylsulfonyl) imide [EMIm]+[Tf2N]− .
registration. The sample preparation is an indispensable part of
method development.
In  the European Pharmacopoeia, there is no guidance as con-
cerns general sample preparation for the assay of any dosage
form; details are included only in the pharmaceutical technologi-
cal procedures. The US Pharmacopoeia, on the other hand, contains
monographs about pharmaceutical products, including supposito-
ries [22]. However, micelle formation can cause problems during
sample preparation. One plausible solution could be the use of
microemulsion liquid chromatography (MELC) but this technique
requires a complicated multicomponent mobile phase system [23].
Our present work is focused on extending the general knowledge
relating to the analysis of suppositories, which can help those who
choose rectal suppositories for drug delivery from both analytical
and technological aspects; as such developments are  conducted in
parallel.
In Hungarian pharmaceutical practice, moulded supposito-
ries are formulated predominantly with three suppository bases:
hard fat (WitepsolW 35, adeps solidus in Hungarian practice), a
hydrophilic base, which contains: macrogol 1540 and Span 20, as
massa macrogoli. Third is adeps solidus compositus, which con-
tains surfactants. In fact it  is Witepsol W35  with Tween 20 and
Tween 61. We  will refer to this base in the present work as W35TT.
A new HPLC method for the analysis of  suppositories containing
aminophenazone as model compound was previously developed
and validated by our research group (unpublished data). In that
work a new sample preparation method was elaborated for the
recovery of the drug from hard fat or hydrophilic matrices. The
method was intended to be applied to W35TT-based suppositories,
too. However, in that case, with the well-established sample prepa-
ration method, the quantity of  drug released was between 80% and
90%, which did not fulﬁl the requirements (95–105%) of the rele-
vant ICH guideline. We present here a possible explanation and a
solution for this phenomenon.
2. Materials and methods
2.1. Materials and instruments
The following materials were used: 4-dimethylaminoantipyrine
(hereafter aminophenazone) (Sigma–Aldrich, St. Louis, MO,  USA),
paracetamol (Ph.Eur. 6.0, Phoenix Pharma Zrt., Hungary, Lot. No.:
1011204), methanol (Chromasolv for HPLC, Sigma–Aldrich, St.
Louis, MO,  USA), acetonitrile (VWR, Prolabo, Fontenay, France),
sodium acetate (Reanal, Budapest, Hungary), acetic acid 96%
(VWR, Prolabo, Fontenay-sous-Bois, France), sodium hydroxide
(Reanal, Budapest, Hungary), sodium chloride (VWR, Prolabo, Leu-
ven, Belgium), potassium dihydrogenphosphate (Spektrum 3D,
Debrecen, Hungary) and potassium hydroxide (Reanal, Budapest,
Hungary), Suppositorium antipyreticum pro parvulo FoNo VII.
(Naturland Ltd., Hungary, Lot. No.: 1938-1112 and Parma Produkt
Ltd., Hungary, Lot. No.: 1209-1106). Throughout the experiments,
HPLC grade solvents were used. The aqueous solutions were pre-
pared with triple distilled water. During the spectrophotometric
measurements, methanol (VWR, Prolabo, Fontenay-sous-Bois,
France), TWEEN® 20 (Sigma–Aldrich, St. Louis, MO,  USA) and
TWEEN® 60 (Sigma–Aldrich, St. Louis, MO,  USA) were used.
The suppository bases applied were hard fat and W35TT (Uni-
versity Pharmacy, University of Szeged, Szeged, Hungary). Adeps
solidus is ofﬁcially included in  Ph.Eur. as hard fat. W35TT is a special
lipohydrophilic base, which is included ofﬁcially in Fo.No. (Formu-
lae Normales, the Hungarian collection of  standard prescriptions.)
It is a  mixture of 95% (w/w) of  hard fat, 2.5% (w/w) of Tween 20  and
2.5% (w/w) of Tween 61. In consequence of procurement issues
relating to Tween 61, Tween 60 is nowadays used instead.
For eluent degassing and sample sonication a  DLS 310-T
DONAU-LAB-SONIC ultrasonic bath was  used.
HPLC measurements were carried out on a Shimadzu Promi-
nence UHPLC system (Shimadzu Corp., Japan) equipped with an
LC-20AD pump, a 4-port solenoid mixing valve, a CTO-20A col-
umn  oven, a DGU-20ASR degasser, and an SPD-M20A UV/VIS PDA
detector with a 10 mm  optical path length ﬂow cell. Samples were
injected via a Rheodyne 6-port manual injector valve ﬁtted with a
20 ml sample loop. Separation was achieved on a  Hypersil ODS (C18)
150 mm  × 4.6 mm,  5 mm column (Thermo Scientiﬁc, Keystone, UK).
Data acquisition and peak integration were effected with LCSolu-
tion (Shimadzu Corp., Japan) chromatographic data acquisition and
processing software.
Spectrophotometric measurements were carried out  on a
Shimadzu UV-1601 UV-vis double-beam spectrophotometer.
Throughout the measurements, quartz cells with 10 mm  optical
path length were used. The spectrophotometric data were eval-
uated with Microsoft Excel.
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Table  2
Surfactant concentration ranges of the CMCs determination.
Concentration (mM)
Tween 60 0  0.03 0.04 0.05 0.06 0.08 0.09 0.1 0.2 0.3 0.5
Tween 20 0 0.04 0.05 0.06 0.07 0.08 0.1 0.3 0.5
Tween 20 and 60 0  0.001 0.005 0.01 0.02 0.03 0.04 0.05 0.06 0.08 0.1  0.3 0.5
1H NMR  spectra were recorded on  a  BRUKER Avance DRX 500
spectrometer at room temperature, with a deuterium lock. There
was no water suppression during the experiment The carrier fre-
quency (O1) was placed at 7.01 ppm and a 16.00 ppm wide region
was detected, the excitation was carried out with a  30◦ pulse
(PW90 = 12.5 ms), the interpulse delay was set to 3 s, the acquisi-
tion time was 2.05 s and 8 transients have been collected into 32 K
datapoints. The spectral processing included an exponential ﬁlter-
ing with 0.3 Hz, zero-ﬁllig to 64 K datapoints and a complex Fourier
transformation. The data-collection and data-processing were car-
ried out using Bruker XWIN-NMR 3.1 software.
2.2. Methods
2.2.1. Preparation of hard fat-based suppository containing
aminophenazone as model compound for HPLC analysis
The suppository was weighed on an analytical balance, and was
then placed into 15 ml of  a  mixture of methanol–water (50:50, v/v).
The suppository was melted on a  40 ◦C  water bath and the fatty
phase was frozen by placing the vessel in ice. The liquid was ﬁl-
tered through moistened cotton to separate the frozen fat from
the solution. The ﬁltrate was collected in a 50 ml  volumetric ﬂask.
The beaker was washed with once 15 ml  and twice 5 ml of  sol-
vent and the washing solvent was combined with the solution in
the volumetric ﬂask, which was then made up to volume with the
same solvent. 0.3 ml of stock sample solution obtained this way
was diluted to 10 ml  and ﬁltered through a  0.45 mm pore size nylon
membrane ﬁlter. The clear ﬁltrate was injected into the HPLC sys-
tem.
2.2.2. Preparation of W35TT-based suppository containing
paracetamol as model compound for HPLC analysis
The suppository was  weighed on an analytical balance, and
was then placed into a beaker containing 15  ml  mixture of
methanol–acetonitrile–potassium dihydrogen phosphate (pH 6.3;
0.05 M)  (50:5:45, v/v/v) (later: solvent), 1 ml  5 M sodium chloride
and 2 ml  1  M sodium hydroxide. The suppository was  melted on
a 40 ◦C water bath. After that the beaker with the solution was
placed into ultrasonic bath for 30 min. The following steps of sam-
ple preparation were the same as  in Section 2.2.1 beginning with
ﬁltration.
2.2.3. Aminophenazone determination with HPLC
Aminophenazone content was determined with an HPLC
method. The mobile phase was methanol–sodium acetate (pH
5.5; 0.05 M)  (60:40, v/v). The pH of the sodium acetate buffer
solution was set to 5.5 with acetic acid. The ﬂow rate of  the
reversed-phase isocratic eluent was 1.5 ml/min and the run time
was 5  min. The chromatographic column was thermostated at
30 ◦C. The chromatograms were recorded at 243 nm. The retention
time of aminophenazone was 1.8 min.
2.2.4. Paracetamol determination with HPLC
The mobile phase during the quantitative determination of
paracetamol was acetonitrile–potassium dihydrogen phosphate
(pH 6.3; 0.05 M)  (10:90, v/v). The buffer was prepared with potas-
sium dihydrogen phosphate and the pH of the solution was
adjusted to 6.3 with 1 M potassium hydroxide solution. The ﬂow
rate, the run time and the column temperature were the same as
described in Section 2.2.3. The chromatograms were recorded at
241 nm.  The retention time of aminophenazone was 2.3 min.
2.2.5. Active substance identiﬁcation by NMR spectroscopy
The stability of  the prepared samples was veriﬁed to make
sure that the applied sample preparation method did not
cause any degradation or decomposition of the active substance
(aminophenazone or paracetamol) and that its structure remained
unchanged throughout the experiment. The measurements were
carried out at 25 ◦C.
The analytical sequence for both model compounds incorpo-
rated the measurement of a reference solution, which contained
the appropriate compound in the solvent used during the chro-
matographic sample preparation, and the sample solution itself.
The method of sample preparation for the HPLC measurements had
to be altered slightly as the NMR  studies required higher concentra-
tions of the active substances. A 5-fold amount of  aminophenazone
or paracetamol (500 mg)  was  therefore dissolved in  the appropriate
solvent to 50 ml in the case of the reference solutions. The sample
solution was  prepared similarly to the reference solution, except
that one W35TT blank suppository was  dissolved in the solvent
together with 1 ml of 1 M sodium hydroxide and 1 ml of 5 M sodium
chloride solution. For the paracetamol measurements, 500 mg of
substance was  dissolved for the reference solution in 50 ml  of  sol-
vent described in Section 2.2.2.  The solution modelling the sample
was prepared by dissolving 500 mg  of paracetamol, and placing
one blank W35TT suppository in  the ﬁrst 15  ml of  solvent. Micelle
demulsion was achieved according to Section 2.2.2 except the last
dilution step. 10% (v/v) of D2O was added to each sample before the
NMR  measurements.
2.2.6. CMC determination
We determined the CMCs of the components present in the
aminophenazone-containing test suppositories in  the applied
solvent mixture: methanol–water (50:50, v/v). We used spec-
trophotometry for the measurement of  the CMCs of the non-ionic
surfactants Tween 20 and Tween 60. Three series of solutions were
prepared with a constant amount of hard fat and increasing con-
centrations of  the two surfactants, either separately or together.
The concentrations used are listed in  Table 2.
The concentration range for the combined surfactants was
determined from the data for the initially characterized individual
Tween 60 and the Tween 20. The highest concentration in the series
was always 0.5 mM,  which corresponds to that of  both surfactants
in the sample solution in  the analytical method for suppositories
containing W35TT.
The pseudoabsorbances (turbidity) of  the series of solu-
tions were determined at 550 nm at ambient temperature. The
absorbances obtained in this way  were plotted against surfac-
tant concentrations. The linear regions of the plots were ﬁtted by
straight lines and the intersection of the straight lines gave the con-
centration of the CMC. The CMC  can be identiﬁed as the breakpoint
of the absorbance vs. concentration curve [24,25].
2.2.7. Dissolution test  of hard fat and W35TT suppositories
Dissolution tests were carried out in a Hanson SR8+ dissolu-
tion tester equipped with basket apparatus. Commercially available
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Fig. 1. Recovery of aminophenazone and paracetamol. (a) Effect of NaCl concentration. (b) Effect of pH. (c) and (d) Effects of pH at constant c(NaCl) = 100 mM. Vertical
bars represent the mean of 3 independent measurement (n =  3), error bars show the standard deviation of the three data. Covariances between the  independent variable
(concentration) and the dependent variable (recovery) for plot a =  28.67; b  = −13.47; c = 58.71 and d =  75.38.
suppositories prepared for children containing aminophenazone
and either hard fat or W35TT were tested. Dissolution medium,
potassium dihydrogen phosphate buffer (pH 7.5; 0.05 M),  was ther-
mostated to 37 ◦C. The agitation speed was 50 RPM. Samples were
collected at 5, 10, 15, 30, 45, 60 and 120 min  and tested by HPLC
with the system described in Section 2.2.3.
3. Results and discussion
As W35TT is based on hard fat, it seemed reasonable to choose
the sample preparation method described in Section 2.2.1 for hard
fat as the starting point for the development. However, our expec-
tations were not fulﬁlled; the recovery of  the API from the W35TT
base was only 88%. The surfactants formed micelles within the sup-
pository base, which encapsulated some of  the API. The sample
preparation procedure described in Section 2.2.1 for hard fat was
not suitable for quantitative release of the drug from the micelles
for the analysis. This caused the difference in recovery between the
two  bases. In order to achieve a satisfactory release, the micelles
had to be broken down to gain access to the trapped drug. It was
presumed that salting-out might be a suitable method to solve this
problem.
3.1. Effect of sodium chloride concentration on drug recovery
The procedure applied in the case of hard fat was  amended with
an additional step by  adding sodium chloride solution in increas-
ing concentrations to the ﬁrst 15 ml of solvent in order to study
the micelle-opening effect of salting-out. At all levels, two paral-
lel samples were prepared. The sodium chloride concentrations
applied were 0, 50, 100, 150 and 200 mM.  HPLC analysis revealed
that the recovery from all of the samples remained below 95%. Fig. 1
demonstrates that the increasing sodium chloride concentration
did not correlate with the observed release. Calculated covariance
between the concentrations and the recoveries suggest a  slightly
increasing relationship, which was possibly due to the minor CMC-
decreasing effect of strong electrolytes [26,27]. The question may
arise whether further increase of sodium chloride concentration
could have improved the recovery sufﬁciently. On the other hand
higher sodium chloride concentration would probably have caused
the precipitation of the salt in the mobile phase as sodium chloride
has solubility one order of magnitude lower in methanol than in
water. Precipitation could damage the silica core of the column;
therefore higher salt concentrations were not tested.
3.2. Effect of pH change on drug recovery
Micelle formation can be inﬂuenced by change of pH [28]. The
API recovery was therefore studied in analytical samples contain-
ing increasing sodium hydroxide concentrations. The additional
step in  this case was the addition of  5 M sodium hydroxide solu-
tion to the initial 15 ml of extraction solvent during the melting of
the suppository. Two  parallel samples were prepared, in which the
concentrations were 0, 20, 40, 60 and 80 mM.  The HPLC analysis
indicated that none of the recovery results reached the lower limit
of the required range of 95–105% at any sodium hydroxide con-
centration. Similarly to the sodium chloride concentration study,
these results did not exhibit any correlation with the increasing
base concentration. The covariance of  the series of data (see cap-
tion of  Fig. 1) indicates a  negative relationship. Therefore higher
sodium hydroxide concentrations were not studied.
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Fig. 2. 1H NMR spectra of aminophenazone and paracetamol standards and samples. The signals marked with letters prove that no decomposition takes place in the sample
solution treated with strong base. Peaks a and b of paracetamol are shifted to the right by 0.2 ppm due to the deprotonation of the OH and NH groups in  the  alkaline medium.
3.3. Effect of ultrasonic treatment on drug recovery
Micelles can be effectively destroyed by ultrasonic treatment.
Due to the ineffectiveness of pH change and salting out, we applied
30 min  ultrasound on  3 parallel preparations of suppositories. Aver-
age recovery was (92.6 ± 2.8)%. Due to the fact that during longer
ultrasonic treatment the transfer medium is warming, longer agi-
tation times were not applied. The ineffectiveness of the individual
effects described in Sections 3.1–3.3 led us to study the combined
effect of sodium chloride, sodium hydroxide and ultrasonic treat-
ment simultaneously.
3.4. Combined effect of sodium chloride and sodium hydroxide on
the drug recovery
The combination of  sodium chloride and sodium hydroxide was
tested together with an additional 30 min  ultrasonic treatment.
Constant, 100 mM sodium chloride and 0, 10, 20 or 40 mM  sodium
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Table 3
Calculation of CMCs from the data of ﬁtted straight lines.
Slope ± SD Intercept ± SD Intersect (mM)
Tween 20 0.4 ± 0.110 0.24  ±  0.033 0.084
2.8 ± 0.485 0.04 ±  0.027
Tween 60 0.52 ± 0.039 0.12  ±  0.011 0.061
4.1 ± 1.022 −0.096 ±  0.047
Tween 20 +  Tween 60 2.1 ± 0.163 0.75  ±  0.040 0.040
12.6  ± 2.083 0.34  ±  0.032
Tween 20 +  60 with salt  and  base 0.07 ± 0.011 1.99 ±  0.199 0.324
0.529 ± 0.008 −0.09 ±  0.037
hydroxide were applied. The recovery results were favourable at 20
and 40 mM sodium hydroxide: 95.7% and 98.0%, respectively. Fig. 1
clearly reveals a correlation between the sodium hydroxide con-
centration and the recovery of  the API when sodium chloride was
present in the sample. The application of 100 mM  sodium chloride
and 40 mM sodium hydroxide was suggested.
This sample preparation method was also tested on  paraceta-
mol. Samples were prepared by the combined sodium chloride and
sodium hydroxide addition method described in Section 2.2.2.  The
suppository was modelled by combining the blank hard fat sup-
pository, Tween 20 and Tween 60 in  the appropriate proportion
and exactly weighed 100 mg of  paracetamol. The sodium hydroxide
concentration was set to 0,  10, 20 or 40 mM during the experiment.
The recoveries demonstrated by HPLC analysis are presented in
Fig. 1 plot d. In the case of paracetamol, 40 mM sodium hydrox-
ide was required to liberate the API entirely. The average recovery
was found to be 98.4%.
Covariance values for plots c and d  of Fig. 1 express a strong
positive relationship between the increase of the hydroxide con-
centration and the change of the recoveries. These values are
signiﬁcantly higher than those determined for plots a and b of Fig. 1.
3.5. Stability of the drugs during sample preparation
In both cases, the drugs were subjected to treatment with strong
base. Sodium hydroxide is suggested to be used between 20 and
40 mM,  but it must be ensured that the drugs do not suffer degrada-
tion during the treatment. The ﬁrst check was during the HPLC runs,
where the spectra of the samples and the pure substances proved
to be identical. The retention times were also found to be similar.
Finally, the 1H NMR  spectra of  the pure standards and the treated
samples were also recorded. In the assigned spectra of paracetamol,
the signals of the OH and NH protons are not visible due to the fast
exchange with water. It  is clearly seen in the paracetamol sample
spectrum that, due to the deprotonation of  the OH and NH groups
with the increase of pH, the chemical shift of the aromatic protons
decreases by 0.2 ppm. In the case of  aminophenazone, no  depro-
tonation takes place, and thus there is no change in the chemical
shifts.
The overlaid spectra showed no  signiﬁcant difference, i.e.
no new peaks were detected, which conﬁrms that the samples
remained intact during the sample preparation (Fig. 2).
3.6. CMCs of Tween 20 and Tween 60
The CMCs of  Tween 20 and Tween 60 were determined in the
presence of hard fat by measuring the turbidity of solutions with
different surfactant concentrations at 550 nm.  Turbidity was plot-
ted against surfactant concentration. Straight lines can be ﬁtted
to each series of points, the intersect of  which gives the CMC  in
the speciﬁc solvent system. This intersection can also be identi-
ﬁed as the breakpoint of  the curve. The parameters of the ﬁtted
straight lines and their intersects are presented in Table 3.  In
methanol–water (50:50, v/v) as solvent the CMC  of Tween 20 was
0.084 mM,  that of Tween 60  was 0.061 mM,  and that of the two
surfactants together was 0.040 mM.
These results are in  good agreement with the trends reported
in previous studies. The slight differences from the literature data
can be attributed to the different measurement techniques and the
different solvents [15,18].  The solvent in this case, an equivolume
mixture of  water and methanol, could increase the CMC. Short-
chain alcohols such as methanol or ethanol are known to decrease
the hydration of the ethyleneoxide chains of non-ionic surfactants,
so the observed trend in the CMC  increase is in  good agreement
with this explanation [29].  The tendencies earlier found for differ-
ent Tween substances can be observed in our results too: the CMC
of Tween 20 is higher than that of  Tween 60. Moreover, the two
surfactants together give a signiﬁcantly lower CMC, which is also
characteristic [14]. It is obvious that the applied surfactant concen-
tration in the suppository base is well above the determined CMC,
which explains the micelle formation and the decreased recovery
of drug as compared with the “pure” hard fat.  Although the applica-
tion of  surfactants in the suppository base has a beneﬁcial effect on
the formulation properties of  the material and on the drug release
in the body, the amounts of surfactants must be optimized to avoid
the analytical pitfall of  failing the recovery study. Too high a  sur-
factant concentration will always pose a potential risk of analytical
error.
This problem raises the question of how micelle formation inﬂu-
ences drug release during therapeutic application. As the problem
appeared during the melting of  the suppository for analytical sam-
ple preparation, the question arises whether this phenomenon
would cause homogeneity problems at surfactant concentrations
higher than the CMC  in suppositories produced in the industrial
technology, which is based mainly on moulding techniques for
large quantities. Our research group is conducting further studies
to ﬁnd answers for these questions.
The complex sample preparation method, which was tested
with two different model compounds, is rapid and effective in the
case of suppository bases containing surfactants to enhance the lib-
eration of the encapsulated drugs. The success of the development
can be explained through the micelles losing their colloidal sta-
bility due to the loss of  electrostatic interactions, which is caused
by the addition of  electrolytes. The mechanism is similar to that
in formulations with targeted drug release. This hypothesis was
proven by determining the CMC  of Tween 20 and Tween 60  in a
medium where ﬁnal sodium chloride concentration was  100 mM
and sodium hydroxide concentration was 40 mM.  The results can
be seen in  Fig. 3. The CMC  of  the combined surfactants is about 5
times higher in the presence of  salt and base than in  the absence of
them. The applied salt and base concentration combined with the
ultrasonic treatment was  sufﬁcient to raise the CMC  of the system
so that the surfactants within the suppository could not assemble
into micelles entrapping part of  the API.
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Fig. 3. Turbidimetric plots for the  determination of  the CMCs of Tween 20  and Tween
60.
3.7. Dissolution proﬁle of different base suppositories
Six dosage units were tested from both hard fat and W35TT
containing suppositories according to the parameters described in
Section 2.2.7. It can be seen in Fig. 4 that dissolution rate from
solid fat based suppositories is slower in the time range critical
for the in vivo effect and until 120 min  only 70% of  the drug is
released. W35TT based suppositories saw saturation from 60 min
(88.9 ± 10.9%). On the other hand it  should be noted that during
Fig. 4. Dissolution proﬁles of  aminophenazone containing hard fat (d) and W35TT
() suppositories.
these experiments the volume of dissolution medium was  900 ml
where the concentration of  Tween 20 is 0.0244 mM and concentra-
tion of Tween 60 is 0.0228 mM,  which is signiﬁcantly lower than in
case of  our analytical samples. Application of such large volumes for
sample preparation to avoid micelle formation is not recommended
in routine laboratories. Furthermore it  is worth for consideration
that dissolution rate in large volumes is inﬂuenced by surfactants
favourably because their concentration fall below their CMC, but
this for sure cannot model the physiological conditions where the
volume of rectal ﬂuid is only 2–3 ml.  In such a small volume the
surfactant concentration will be deﬁnitely higher than those in our
analytical samples and will fall above the CMC  in every case. If
2.5 ml rectal ﬂuid volume is hypothesized concentration of Tween
20 will be 9.76 mM  and concentration of Tween 60  will be 9.12 mM
accounting for even higher extent of micelle formation.
4. Conclusions
We  have developed an  adequate sample preparation method
for Tween 20 and Tween 60 containing hard fat based supposito-
ries. We have proved that micelles are being formed in the sample
solution and successfully destabilized them by applying 100 mM
sodium chloride and 40 mM sodium hydroxide concentration and
30 min  ultrasonic treatment, which made the complete release of
two physico-chemically different APIs possible. Provided that there
are appropriate chromatographic methods at hand, the developed
sample preparation method could be utilized for the determination
of other drug molecules from surfactant containing suppositories
as well.
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Abstract The availability of suppositories in Hungary, especially in clinical pharmacy practice, is
usually provided by extemporaneous preparations. Due to the known advantages of rectal drug
administration, its beneﬁts are frequently utilized in pediatrics. However, errors during the extem-
poraneous manufacturing process can lead to non-homogenous drug distribution within the dosage
units. To determine the root cause of these errors and provide corrective actions, we studied sup-
pository samples prepared with exactly known errors using both cerimetric titration and HPLC
technique. Our results show that the most frequent technological error occurs when the pharmacist
fails to use the correct displacement factor in the calculations which could lead to a 4.6% increase/
decrease in the assay in individual dosage units. The second most important source of error can
occur when the molding excess is calculated solely for the suppository base. This can further dilute
the ﬁnal suppository drug concentration causing the assay to be as low as 80%. As a conclusion we
emphasize that the application of predetermined displacement factors in calculations for the formu-
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lation of suppositories is highly important, which enables the pharmacist to produce a ﬁnal product
containing exactly the determined dose of an active substance despite the different densities of the
components.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.
1. Introduction
Drugs used for rectal administration are frequently supplied by
independent pharmacies and especially clinical pharmacies.
This route of administration is very important in pediatrics.
Pharmaceuticals used for the treatment of fever, pain, spasms,
asthmatic symptoms and vomiting can be administrated rec-
tally (Abd-el-Maeboud et al., 1991; Dahl et al., 2000; Fumo-
leau et al., 1997; Kauss et al., 2012; Okabayashi et al., 2012;
Richter et al., 2012; Sabchareon et al., 1998; Shiohira et al.,
2009; Tinner et al., 2013). Approximately 80% of the suppos-
itories used in Central Europe are produced extemporaneously
using the molding technique. In clinical pharmacies quantities
of 100–300 and in independent pharmacies 10–12 suppositories
are generally molded as one batch. Suspension suppositories,
in particular, are formulated with a solid fatty vehicle (‘‘e.g.’’
Witepsol 35) or a combination of this suppository base with
surfactants (Rowe et al., 2003). The core of this technology
is the dispersion of the ﬁnely powdered drug with the molten
suppository base. After which, the suspension is molded under
continuous stirring. Fatty suppository bases have very low vis-
cosities, which decrease still further with an increase in temper-
ature, causing rapid sedimentation of the suspended particles
and leading to a non-homogeneous product. When the liquid
mass is molded at around the solidiﬁcation point, solidiﬁcation
occurs immediately as the mass enters the mold, making fur-
ther additions of the base and drug impossible. In the calcula-
tion of the suppository base weight, the following formula
must be applied (Eq. (1)):
Tm ¼ Eÿ
Xn
i¼1
fi  si ð1Þ
where Tm is the suppository base to be weighed, E is the cali-
bration constant of the mold, fi is the displacement factor of
the ith component and si is the weight of the ith component.
During the calculation of a correct formula, it is not sufﬁcient
to subtract the weight of the solid components from the ﬁnal
weight of the suppository to obtain the required amount of
the suppository base. We must also know the value of E for
the speciﬁc mold and speciﬁc suppository base, which can be
determined through independent measurements. Ten supposi-
tories are usually prepared with the mold, using the pure base,
and after cooling they are weighed and the average suppository
weight is calculated. This average value will be used as the cal-
ibration constant for the mold for any speciﬁc base. Since the
density of the active ingredient (hereinafter referred to as
‘‘API’’) incorporated into the suppository base can differ from
that of the base itself, the displacement factor (f) is required to
compensate for the difference in densities. The value of f,
which shows how much base will be displaced by a unit weight
of an API, can be calculated from the following equation (Eq.
(2)):
f ¼
100  ðEÿ GÞ
G  x
þ 1 ð2Þ
where E is the weight of the blank suppository containing only
base, G is the weight of the suppository containing an API in a
known concentration, and x is the API content of the suppos-
itory in weight percentage.
If the pharmacist fails to carry out the steps in strict accor-
dance with these rules, signiﬁcant deviations will be observed
in the results for the homogeneity of the batch and in the total
drug content of the batch.In this research we report on an
investigation of samples prepared in pharmacies, with a special
emphasis on the homogeneity and the total API content of the
batches. The circumstances of the preparation of the supposi-
tories were known in all cases and are presented. In pharma-
cies, the f-values of the most frequent APIs in the most
common bases are not generally available. According to a
good manufacturing practice pharmacists apply the participle
of overage during the calculation of the batch composition,
but an incorrect calculation for the amount of vehicle required
and other technological errors may lead to serious deviations
in the ﬁnal dosage for the individual suppositories (Allen,
2007; Miseta and Soo´s-Csa´nyi, 2011; Ra´cz and Selmeczi,
1991).
2. Materials and methods
2.1. Materials
HPLC grade solvents and triple-distilled water were used dur-
ing the chromatographic measurements. For the preparation
of the HPLC mobile phases and sample preparation solvents,
the following materials were used: 4-dimethylaminoantipyrine
(Sigma–Aldrich, St. Louis, MO, USA), methanol (Chromasolv
for HPLC, Sigma–Aldrich, St. Louis, MO, USA), sodium ace-
tate (Reanal, Budapest, Hungary), acetic acid 96% (Molar
Chemicals, Budapest, Hungary), sodium hydroxide (Reanal,
Budapest, Hungary) and sodium chloride (VWR, Prolabo,
Leuven, Belgium). Volumetric solutions for the cerimetric
titrations were prepared with the following materials: ceriu-
m(IV) sulfate tetrahydrate (Panreac, Barcelona, Spain), sulfu-
ric acid 96% (Farmitalia Carlo Erba, Milano, Italy) and
ferroin-solution, 1/40 M (Reanal, Budapest, Hungary).
Commercially-made suppositories were used during the
comparisons for the analytical methods. The reference product
was Suppositorium antipyreticum pro parvulo FoNo VII.
Naturland (Naturland Magyarorsza´g Kft., Budapest, Hun-
gary), which contained 150 mg of aminophenazone per sup-
pository in a solid fatty suppository base. One box contains
six suppositories (Paa´l, 2003).
Samples were also prepared in regular pharmacies by the
molding technique, according to the following procedure.
Ten suppositories were obtained from 15 independent pharma-
cies with a labeled claim of 100 mg of aminophenazone in each
suppository. The choice of vehicle for the suppository was left
to the responsibility of the pharmacist at the site. Practically all
of the samples were prepared with a solid fatty base. In each
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case, predetermined technological errors (known to us) were
made during the sample preparation.
2.2. Test methods
2.2.1. Cerimetric titration
The basis of the drug content determination is the use of a cer-
imetric redox titration method (Ro´zsa, 1953), During this as-
say the nascent oxygen evolved from the reaction of Ce(IV)
with water oxidizes aminophenazone. The end-point of the
titration is observed by the change in color of ferroin added
as the indicator. During the sample preparation, whether from
the commercially prepared suppository or the extemporane-
ously prepared ones, one suppository is melted over a 40 °C
water bath and 3 replicate samples of 0.20–0.30 g are weighed
from the molten mass into titration ﬂasks. A 10.0 ml portion of
15% sulfuric acid is added to each sample and the mixture is
heated to 40 °C to extract the API from the suppository base.
The mixture is then cooled to room temperature. A 15 ml por-
tion of distilled water is added, and after mixing, one drop of
ferroin as indicator is added. This is then titrated with 0.05 M
cerium(IV) sulfate volumetric solution until the color of the
solution changes from orange to green and remains green for
at least 1 min (Paulenova et al., 2002; Townshend, 2005).
2.2.2. Assay of aminophenazone by HPLC
HPLC measurements were carried out on a Shimadzu Promi-
nence UHPLC system (Shimadzu Corp., Kyoto, Japan)
equipped with an LC-20AD pump, a four port solenoid mixing
valve, a CTO-20A column oven, a DGU-20ASR degasser, and
an SPD-M20A UV/VIS PDA detector with a 10 mm optical
path length ﬂow cell. Sample injection was performed with a
Rheodyne six port manual injector valve ﬁtted with a 20 ll
sample loop. Separation was achieved on a Hypersil ODS
(C18) 150 · 4.6 mm, 5 lm column (Thermo Scientiﬁc, Key-
stone, UK). Data acquisition and peak integration were car-
ried out with the LC Solution (Shimadzu Corp., Kyoto,
Japan) chromatographic data acquisition and processing
software.
The mobile phase was methanol:sodium acetate (pH 5.5;
0.05 M) (60:40, v/v). The pH of the sodium acetate buffer solu-
tion was adjusted to the desired value with acetic acid. The
ﬂow rate of the reversed-phase isocratic eluent was 1.5 ml/
min and the run time was 5 min. The chromatographic column
was thermostated at 30 °C throughout the separation. The
chromatograms were recorded at 243 nm. The retention time
of aminophenazone was found to be 1.8 min. The applied
method was validated. The samples were prepared with a tech-
nique elaborated previously by our research group. The exactly
weighed suppository was melted over a 40 °C water bath in a
50:50 (v/v) methanol:water mixture. After identiﬁcation of
the suppository base on the basis of its physicochemical prop-
erties, the base was separated from the solution if necessary.
The sample solution was then ﬁltered through a 0.45 lm pore
size nylon membrane ﬁlter. The solution was injected onto the
HPLC through the Rheodyne injector valve.
3. Results and discussion
3.1. Comparison of the cerimetric titration and the HPLC
method
We compared the two analytical methods by measuring two
sets of six commercially-made suppositories from the same
batch having the exact lot number. The individual assays for
the suppositories were carried out by either the volumetric or
the chromatographic technique. All of the ﬁnal results (the
averages of the three replicates for each of the six suppositories
in the case of the titrimetric method, and the individual sup-
pository assay value in the case of the chromatographic deter-
mination) fell within the range 95–105%, which conforms to
the strictest requirements of the European Pharmacopoeia.
The individual content data are presented in Table 1.
It should be noted that the volumetric results exhibit a lar-
ger standard deviation than that of the chromatographic re-
sults, but the preparation of samples for titration (one total
of 18 replicate samples prepared from the molten suppository)
involves a higher level of uncertainty, and this can therefore be
considered acceptable. A comparison of the two methods re-
veals that both can be used for the analysis of suppositories
containing aminophenazone.
3.2. Dosage uniformity study of extemporaneously prepared
suppositories
We additionally studied pediatric suppositories with the
composition described in Section 2.1. All samples were from
different Hungarian independent pharmacies, and each sample
consisted of 10 individual suppositories. The manufacturing
technology for each of the samples was known to us with the
pharmacists committing intentional technological errors
during the preparation of the suppositories. The extemporane-
Table 1 Assay results for factory-produced suppository samples, measured by cerimetric titration or the HPLC method.
Sample Cerimetric titration Sample HPLC
Replicates% Average cont.% Content%
S1 101.6 107.2 103.5 104.1 S7 103.9
S2 98.9 99.3 97.5 98.5 S8 104.9
S3 106.3 100.7 100.3 102.4 S9 102.8
S4 96.1 100.7 97.1 98.0 S10 102.3
S5 100.9 110.4 102.1 104.5 S11 103.9
S6 103.6 104.0 104.7 104.1 S12 104.6
Average 101.9 103.7
SD 2.93 1.01
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ously prepared samples (containing 10 suppositories) from
pharmacies Ph1–Ph9 were measured with the HPLC technique
described in Section 2.2.2. The extemporaneously prepared
samples (containing 10 suppositories) from pharmacies
Ph10–Ph15 were tested for dosage uniformity with the titrimet-
ric method presented in Section 2.2.1. All of the ﬁndings (see
Fig. 1) were compared on the basis of the results given in
Section 3.1. It can be stated that two samples conformed to
the speciﬁcations of Ph. Eur. 7.8, ‘‘i.e.’’ the individual assay
values fell within the range 85–115% at level 1, and one further
sample would probably have conformed to the level 2 speciﬁ-
cation of 75–125% (Ph Eur 7.8). For the remaining samples,
generally either lower individual assay results or (in 2 samples)
signiﬁcant non-homogeneity was found, which are justiﬁed by
standard deviation values visible in Table 2.
3.3. Effects of f-value on the assay results
The possible consequences of the most common errors can be
illustrated utilizing a theoretical example. If the pharmacist
produced suppositories on the basis of the following parame-
ters: E= 1.7 g; f= 0.78 and s= 0.1 g then, according to
Eq. (1), Tm = 15.22 g for the 10 suppositories. If f-value is
not applied, but only the weight of the API is subtracted from
the value of E, then we have Tm = 16.0, which will result in an
assay which is 4.6% lower than the required value. If this error
is superimposed with the one when the calculated molding ex-
cess is taken solely from the suppository base (taking the re-
quired base for 12 dosage units instead of 10) then the
concentration of one suppository is diluted even further, to
80.3% of the intended theoretical value.
3.4. Effects of stirring on the homogeneity and total assay of the
samples
The suppository mass can be well homogenized by choosing an
appropriate rate of manual stirring or machine-based mixing.
Stirring during the molding process can help avoid the sedi-
mentation of the API in the container. Too slow a stirring rate
is not effective, however too fast a stirring rate may also lead
to errors: since air bubbles may be formed in the mass, which
will decrease the weight of the suppositories. Foam can be
formed from the surfactant-containing bases, or shearing
forces may appear, which decrease the viscosity of the suppos-
itory mass by rheodestruction, causing the rapid sedimentation
of the API. The ideal machine stirring speed for fat-based sup-
positories is recommended as 150 rpm.
The results demonstrate that the stirring technique for
extemporaneously prepared pharmacist suppositories before
and during the molding procedure was appropriate, with the
exception of a small number of serious cases. Those samples
can be considered homogeneous which gave SD 6 10 with re-
spect to the individual suppository assays. A larger deviation
can originate from the lack of stirring during molding, as
may be seen for samples 5, 7 and 16. Extremely large devia-
tions result when both thorough homogenization and stirring
during the molding process are omitted, which maybe ob-
served for samples 6 and 13. If (f) is not applied and the sup-
pository base is used in an excess amount, the assays for the
samples will fall below the lower limit of acceptance. If the
molten mass is not stirred during molding process, the decrease
in the API content becomes more serious since the suspended
material is sedimented, and the mold will contain an API –
which is depleted from the mixture.
4. Conclusions
The results for pediatric suppositories produced extemporane-
ously under predeﬁned conditions in Hungarian independent
pharmacies revealed that serious errors may arise if the rules
used in the pharmaceutical technology for preparing such sup-
positories are not strictly adhered to, and the assay results on
the individual dosage units may be affected. On the other
hand, suppositories prepared with strict adherence to the cor-
rect manufacturing practices conform to the speciﬁcations de-
scribed in Ph. Eur. 7.8. Since extemporaneously prepared
suppository preparations are frequently compounded and sup-
plied in central European clinical pharmaceutical practice be-
cause of the low costs involved, we would encourage the use
of and the inclusion of the f-values for the most common APIs
and for the most common suppository bases into the European
or national pharmacopoeias. To our knowledge the paucity of
this information prohibits the preparation of the ‘‘right’’ dose
for the ‘‘right’’ patient and may even do harm. Calibration of
Figure 1 Mean API content for the samples, with the standard
deviations. An API content in the interval 85–115% is satisfac-
tory. Samples Ph1–Ph9: HPLC results; Samples Ph10–Ph15:
cerimetric titration results.
Table 2 Average assay results on the samples and standard deviations in the homogeneity study. Ph in the sample raw stands for
pharmacy.
Sample Ph1 Ph2 Ph3 Ph4 Ph5 Ph6 Ph7 Ph8 Ph9 Ph10 Ph11 Ph12 Ph13 Ph14 Ph15
Average% 87.7 56.1 75.6 74.8 85.8 84.7 86.9 76.2 49.5 93.7 75.5 70.4 82.9 54.9 78.6
SD 4.8 3.6 3.6 11.1 52.8 11.6 3.0 7.8 7.0 10.2 8.0 7.4 79.7 5.5 14.3
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the mold and the determination of the f-value for these basic
common suppository bases can be accomplished very simply.
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Combined drug products have the advantages of better patient com-
pliance and possible synergic effects. The simultaneous application
of several active ingredients at a time is therefore frequently
chosen. However, the quantitative analysis of such medicines can
be challenging. The aim of this study is to provide a validated
method for the investigation of a multidose packed oral powder that
contained acetylsalicylic acid, paracetamol and papaverine-HCl.
Reversed-phase high-pressure liquid chromatography was used.
The Agilent Zorbax SB-C18 column was found to be the most suit-
able of the three different stationary phases tested for the separ-
ation of the components of this sample. The key parameters in the
method development (apart from the nature of the column) were
the pH of the aqueous phase (set to 3.4) and the ratio of the organic
(acetonitrile) and the aqueous (25 mM phosphate buffer) phases,
which was varied from 7:93 (v/v) to 25:75 (v/v) in a linear gradient,
preceded by an initial hold. The method was validated: linearity,
precision (repeatability and intermediate precision), accuracy, spe-
cificity and robustness were all tested, and the results met the ICH
guidelines.
Introduction
A number of drug products are available on the market for the
treatment of smooth muscle spasm, e.g., in the biliary, renal and
intestinal tracts. For the mitigation of acute renal or gastrointes-
tinal pain, the primary drug of choice is a nonsteroidal anti-
inﬂammatory drug (NSAID) such as paracetamol, acetylsalicylic
acid (ASA) or ibuprofen (1). Such conditions are frequently
treated with combined products, which contain a smooth
muscle antispasmodic together with one or more NSAID painkil-
ler(s) (2). The combination of papaverine hydrochloride (papa-
verine) and ibuprofen or indometacin is nowadays commonly
used, especially for the treatment of dysmenorrhea. As regards
the administration of papaverine, the research focus has shifted
in recent years from the gastrointestinal tract to the coronary ar-
teries (3) and the therapy of an erectile dysfunction (4–6).
Nevertheless, in pharmaceutical practice, papaverine is still com-
monly prescribed as an antispasmodic to relieve gastrointestinal
and menstrual spasms.
When a rapid effect is desired, the active pharmaceutical
ingredients (APIs) can be applied in powder dosage form
without excipients. Analgesic drugs are often formulated as mul-
tidose packed oral powders. An oral powder as a pharmaceutical
dosage form containing solid ingredients, including one or more
APIs with or without excipients. It is generally administered in
or with water or another suitable liquid. It may also be swallowed
directly (7).
Many authors have described the simultaneous determination
of paracetamol and ASA in various pharmaceutical dosage forms
and also in blood or urine samples (8–18), but the available lit-
erature on the HPLC analysis of papaverine is quite limited.
Mostly, the presence of papaverine together with opiates has
been studied (19–27) and many ﬁndings are available as con-
cerns its identiﬁcation in blood samples from opiate drug users
(20, 23, 24, 26, 27). Its UV–vis detection in chromatographic
methods is very rare. The mobile phase compositions applied
are often complex, containing multiple organic modiﬁers, which
are beneﬁcial from the aspect of papaverine, but do not facilitate
the analysis of samples containing paracetamol and ASA too. The
NSAID components of the mixtures would elute within the void
or coelute if the method suitable for paracetamol analysis were
applied. Despite a thorough search, we have found no hits for
the determination of paracetamol, papaverine and ASA with a
single analytical method, and conclude that the simultaneous
RP-HPLC analysis of these three components has not been previ-
ously published.
Experimental
Materials and instruments
The following materials were used in our studies: paracetamol
(Ph. Eur. 6.0, Phoenix Pharma Plc., Hungary, Lot No.: 1011204),
papaverine-HCl (Molekula, Shaftesbury, UK), ASA (Ph. Eur. 6.0,
University Pharmacy, University of Szeged, Szeged, Hungary),
methanol (Chromasolv for HPLC, Sigma-Aldrich, St. Louis, MO,
USA), acetonitrile (ACN) (VWR, Prolabo, Fontenay-Sous-Bois,
France), sulfuric acid 96% (Analyticals Carlo Erba, Milano, Italy),
potassium dihydrogenphosphate (SPEKTRUM-3D, Debrecen,
Hungary) and potassium hydroxide (Reanal, Budapest, Hungary).
Throughout the experiments, HPLC grade solvents were used.
The solvents and the aqueous solutions were prepared with
triple distilled water.
HPLC measurements were carried out on a Shimadzu
Prominence UHPLC system (Shimadzu Corp., Kyoto, Japan)
equipped with an LC-20AD pump, a four-port solenoid mixing
valve, a CTO-20A column oven, a DGU-20ASR degasser and an
SPD-M20A UV/VIS PDA detector with a 10-mm optical path
length ﬂow cell. Samples were injected via a Rheodyne six-port
manual injector valve ﬁtted with a 20-mL sample loop. During
the method development, separation was studied on a Hypersil
ODS (C18) 150  4.6 mm, 5 mm column (Thermo Scientiﬁc,
Keystone, UK), a Luna C18(2), 150  4.6 mm, 3 mm column
(Phenomenex, Torrance, CA, USA) and a Zorbax SB-C18 150 
4.6 mm, 3.5 mm column (Agilent, Santa Clara, CA, USA). Data
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acquisition and peak integration were carried out with LCSolution
(Shimadzu Corp., Kyoto, Japan) chromatographic data acquisition
and processing software. The results were evaluated with
LCSolution and Microsoft Ofﬁce Excel 2007 software. The logD
vs. pH function was predicted with Pallas intelligent chromato-
graphic software (28). The samples were ﬁltered through a
0.45-mm pore size nylon membrane ﬁlter (Millipore Ireland Ltd.,
Tullagreen, Carrigthwohill, Ireland) before the injection.
Sample preparation
For the stock solution, 48.0 mg powder (17.0 mg paracetamol,
26.0 mg ASA and 5.0 mg papaverine in a homogeneous mixture)
was weighed with analytical precision into a 50.0-mL volumetric
ﬂask, dissolved and made up to volume with the solvent, phos-
phate buffer (25 mM, pH 3.43): ACN (85:15, v/v). During the
preparation, the sample was heated to 408C, this step being
required for the complete dissolution of ASA, which has low
solubility (slightly soluble according to Ph. Eur.) in water. For
the working sample solution, 3.0 mL stock solution was diluted
to 10.0 mL and ﬁltered through a 0.45-mmMillipore syringe ﬁlter
before injection.
Results
Method development strategy
As the ﬁrst step of the chromatographic method development,
the properties of the drugs which may inﬂuence the separation
were determined. Particularly, the separation of papaverine and
ASA can be difﬁcult to achieve in view of the speciﬁc pK values
and the logD versus pH curves (Figure 1), which were calcu-
lated with Pallas chromatographic software. The pH of the
applied aqueous mobile phase is one of the key parameters that
affects the separation. The range between 2 and 8 is optimum
from the aspect of the stationary phase, but the range between 1
and 6 is not appropriate for the separation of papaverine, which
contains one basic nitrogen with a pK in the upper part of the
range. In the pH interval 3–8, the ratio of the dissociated and
undissociated forms of ASA changes. At pH .6 (which is beneﬁ-
cial for papaverine separation), ASA peak splitting was observed.
In light of the above ﬁndings, the most challenging task was to
ﬁnd the most appropriate combination of the boundary condi-
tions, where the overall negative inﬂuence on the separation and
elution of the analytes is least. pH 3.4+0.05 was found to be a
reasonable compromise for the pH of the aqueous phase. An
assay of papaverine alone was reported in the application data-
base of Agilent, which involved a similar pH in the aqueous mobile
phase (http://www.chem.agilent.com/Library/applications/596
81112.pdf). In this method, the aqueous eluent contained
25 mM potassium dihydrogenphosphate, but sulfuric acid was
used to adjust the pH so as not to increase the phosphate con-
centration.
It can be seen in Figure 1 that at pH 3.4 paracetamol and most
of the ASA are in an undissociated form. The basic papaverine is
at the beginning of the transient section of the equilibrium,
which can be observed between pH 3 and 6 in the logD curve.
The ratio of the organic modiﬁer of the mobile phase, ACN, was
linearly increased from 7 to 80% during the initial 16 min of the
run, and was then kept constant for 4 min. Between 20 and
22 min, the ratio of the organic modiﬁer was linearly decreased
to the initial level, at which it was held constant during the re-
mainder of the run, to 25 min. A 1:1 (v/v) mixture of methanol
and the mobile phase was suggested as solvent in the literature
method. The ﬂow rate of the mobile phase was 1.5 mL/min and
the separation was achieved on a Hypersil ODS column at 608C.
The results of the runs under the above-described conditions
can be seen in chromatogram (a) in Figure 2, where paracetamol
and ASA were co-eluted. An initial isocratic hold was therefore
inserted into the method before the gradient for the resolution
of the co-elution, because the lower organic content selectively
increased the retention times of the peaks, removing them from
the void. In the new method, we applied a constant 7% ACN
section during the initial 2 min, followed by a similar gradient as
described above. At this point, it became obvious that the hydro-
phobicity of the stationary phase was too low and the retention
of the basic papaverine was too high, so that it could not be
eluted with acceptable peak shape within a reasonable time, al-
though the separation of paracetamol and ASAwas ideal.
For optimization of the peak shape, an alternative column had
to be used. Two columns with different selectivity and with
higher hydrophobicity than that of the Hypersil ODS column
were chosen on the basis of the data to be found in the compara-
tive column selectivity database of Waters (http://www.waters.
com/waters/promotionDetail.htm?id=10048475&locale=en_US)
the Luna C18(2) and the Zorbax SB-C18 stationary phases. It is
clear from chromatogram (b) in Figure 2 that a hydrophobicity
increase of ,1 order of magnitude led to the successful elution
of papaverine. This latter method resulted in the co-elution of
ASA and papaverine on both columns. In order to resolve the
peaks, the can content at the end of the gradient and in the
second isocratic section had to be decreased from 80 to 25%.
This modiﬁcation resulted in suitable peak separation for all
three analytes on both Luna C18(2) and Zorbax SB-C18. ASA and
papaverine were eluted with higher resolution on the more se-
lective Zorbax SB-C18 column. The retention parameters of the
separated peaks on the three different columns are presented in
Table I. It is clear that the Hypersil ODS column was not suitable
for the simultaneous separation of the three components,Figure 1. Log D versus pH curves of paracetamol, ASA and papaverine.
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whereas the Luna C18 and Zorbax SB-C18 columns were equally
appropriate; nevertheless, the results obtained on the Zorbax
SB-C18 column were superior to those the on the Luna C18 sta-
tionary phase as concerns its higher selectivity. Sample chroma-
tograms measured on the three columns are presented in
Figure 3.
The developed method
The mobile phase during the quantitative determination was
a potassium dihydrogenphosphate (25 mM, pH 3.43): ACN
mixture. The details of the solvent gradient are to be seen in
Table II. The buffer was prepared with potassium dihydrogen-
phosphate, and the pH of the solution was adjusted to the
desired value with 1 M sulfuric acid solution. The ﬂow rate was
1.5 mL/min, the run time was 10 min and the column tempera-
ture was 608C. The chromatograms were recorded at 240 nm, at
which wavelength all three components can be detected repro-
ducibly. The choice of the detection wavelength was limited by
the molar absorptivity of ASA, which is ≏1 order of magnitude
lower than those of the other components (29). Although ASA is
the main component of the mixture, its peak intensity is lower
than that of paracetamol. During runs, the UV spectra (200–
300 nm) of the components were collected for identiﬁcation of
the drugs. The column applied during method validation was the
Zorbax SB-C18 150  4.6 mm, 3.5 mm column.
Validation
We present a full validation of the method according to ICH
guideline Q2 (R1) (30), including linearity, repeatability, inter-
mediate precision, accuracy, speciﬁcity and robustness. As the
Figure 3. Comparison of the three stationary phases: (a) Zorbax SB-C18, (b) Luna C18
and (c) Hypersil ODS. It can be observed that papaverine was completely retained on
the Hypersil ODS.
Figure 2. Chromatograms obtained on the Hypersil ODS (a), Luna C18(2) (b) and
Zorbax SB-18 (c) columns.
Table I
Chromatographic Parameters of the Sample Peaks on the Three Columns
Column type Parameter Paracetamol ASA Papaverine
Hypersil ODS k0 0.549 2.866 –
a 0.000 5.224 –
R – 25.511 –
tR 2.323 5.799 –
Luna C18 k0 1.324 3.487 3.937
a 0.000 2.634 1.129
R – 29.949 7.039
tR 3.486 6.731 7.406
Zorbax SB-C18 k0 0.662 2.932 4.102
a 0.000 4.432 1.399
R – 30.844 16.192
tR 2.492 5.897 7.653
k
0 is the retention factor, a is the separation factor, R is the resolution and tR is the retention time.
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method was to be utilized for the rapid quality control of dosage
units, which does not require the method to be stability indicat-
ing, forced degradation studies were not conducted (31).
Linearity
The linearity of the method was examined in the concentration
range between 0.02 and 0.04 mg/mL in the case of paracetamol,
between 0.03 and 0.065 mg/mL for ASA and between 0.006 and
0.013 mg/mL for papaverine, these data corresponding to 70–
130% of the nominal contents of the dosage units. The range
was covered by the use of six solutions, each diluted from two
individually prepared reference solutions, so that the sequence
of the stock solutions used for the dilutions alternated. The peak
areas determined with LCSolution were plotted versus the con-
centrations of the solutions and a straight line was ﬁtted to the
points. The slope of the paracetamol ﬁtted straight line was
2.0171  108, the intercept was 1.5172  103 and R2 was
0.9995. The slope of the ﬁtted straight line in the case of ASA
was 4.9169  107, the intercept was 4.9344  104 and R2 was
0.9997. Finally, the slope of the ﬁtted straight line for papaverine
was 3.1811  108, the intercept was 23.6861  104 and R2 was
0.9997. This demonstrated that in the studied concentration
range the response of the method was linear.
Precision
Repeatability. Repeatability was checked on six individual
samples according to the method described in Section Method
development strategy. For paracetamol and ASA, RSD% proved to
be 0.4 and 0.6%, respectively, both of which are acceptable. The
papavarine results gave the highest RSD%, 1.4%, but this is also
acceptable when the very low nominal amount of drug in the
sample is taken into consideration.
Intermediate precision. The same analysis procedure was
carried out by a different analyst on a different day, using a
freshly prepared mobile phase.
The results for the paracetamol component were an RSD% of
0.7% and a relative difference of 1.3% between the averages of
the repeatability (Day 1) and intermediate precision (Day 2)
results compared with the mean of the average values measured
for each. Both results can be accepted according to the princi-
ples of general pharmaceutical analytical practice. For ASA, the
RSD% of the individual results was 0.9%, while the relative differ-
ence between the repeatability and intermediate precision was
1.2%. For papaverine, the RSD% proved to be 2.1% and the rela-
tive difference of the mean values on the 2 days was also 2.1%.
All three results are in accordance with the appropriate guide-
lines, and are therefore considered acceptable.
Accuracy
The accuracy of the method was studied in the range between
70 and 130% of the nominal content of the powder. The results
are shown in Table III. Although all of the average values fell
between 95 and 105%, it should be mentioned that in the cases
of ASA and papaverine most of the averages were ,100%, while
in the case of paracetamol they were .100%. This may raise a
warning ﬂag, but no trend was observed within the results that
could be correlated with the increasing concentration of the
sample groups.
Specificity
When the procedure was carried out with the solvent as blank
(the sample contained the API without excipients), no peaks
were detected at the retention times of the drugs.
Robustness
Examinations were made of the effects of changing the organi-
c:aqueous ratio in the isocratic phases of the gradient, the pH of
the aqueous phase, the ﬂow rate of the mobile phase and the
temperature of the column on the retention time and on the
shapes of the drug peaks. The results of the robustness studies
(Table IV) demonstrate that the ratio of the aqueous and organic
phases exerted a great inﬂuence on both the retention time and
the peak symmetry of the analyte. Variation of the pH of the
aqueous phase caused only minor shifts in the retention times of
the paracetamol and ASA peaks. The elution of paracetamol was
not inﬂuenced by this parameter at all. In the cases of ASA and
papaverine, the shift of the retention time in the opposite direc-
tion with the increase of pH caused an increase in resolution,
which is in agreement with the increasing polarity of the com-
ponents with pH. The ﬂow rate change caused a minimal change
in the retention time, proportional to the extent of the change.
Flow rate changes did not inﬂuence the peak shape or plate
numbers. Changes in column temperature did not cause signiﬁ-
cant changes in the retention times. Nevertheless, it is note-
worthy that the retention of papaverine decreased with the
decrease of temperature. Finally, variation of the organic:aqu-
eous ratio, both at the start and at the end of the gradient,
caused considerable changes in the peak retention times.
Decrease of the organic modiﬁer content of the initial hold
increased the retention of paracetamol, while increase of the
organic component pushed the peak very close to the void
Table II
Solvent Gradient in the Chromatographic Method Described in Section Method Development
Strategy
Time ACN (%)
0.00 7
2.00 7
4.00 25
8.00 25
8.10 7
10.0 7
Table III
Results of the Accuracy Studies
Level Paracetamol % ASA (%) Papaverine (%)
Rep. Mean RSD Rep. Mean RSD Rep. Mean RSD
70% 1. 103.0 102.5 0.45 100.8 100.1 0.61 98.4 98.1 0.26
2. 102.1 99.8 97.9
3. 102.3 99.7 98.2
100% 1. 101.4 101.9 0.43 98.3 98.5 0.17 98.2 98.7 0.47
2. 102.3 98.7 98.9
3. 102.1 98.5 99.0
130% 1. 100.7 101.7 0.94 97.0 97.6 0.59 95.8 96.8 0.90
2. 102.5 98.1 97.4
3. 102.1 97.7 97.1
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peak. Decrease of the organic modiﬁer content at the end of the
gradient increased the retention of both ASA and papaverine,
this being more signiﬁcant in the case of papaverine. On the
other hand, the papaverine peak shape became more asymmet-
ric and the number of theoretical plates also decreased in this
case. A change in the opposite direction led to decreases in the
retention times of ASA and papaverine, the greater effect being
observed for papaverine and in this case the two peaks came too
close to each other. This last change did not inﬂuence the reten-
tion of paracetamol; only a slight increase in the theoretical plate
number was observed.
The results reveal that the method is robust, and the peaks are
well separated and elute with acceptable symmetry within the
studied boundaries of the parameters.
Discussion
The presented results clearly demonstrate that the most challen-
ging part of the development was to ﬁnd an appropriate station-
ary phase on which all three compounds can be separated with
good peak symmetry and resolution. The Hypersil ODS station-
ary phase proved to be too retentive for papaverine and it was
obvious during the development that good peak shape cannot
be achieved. The application of a stationary phase equivalence
chart led us to the Zorbax SB-C18 and Luna C18 stationary
phases, which were more hydrophobic and more selective
according to the chart data. The increased hydrophobicity of the
stationary phase made it necessary to reduce the ﬁnal organic
modiﬁer content of the gradient. In this way, all three com-
pounds eluted within 10 min and were separated well on both
stationary phases. Another problem was the low solubility of ASA
in water. In organic solvents such as methanol or ACN, it is freely
soluble, but a higher organic content of the mobile phase would
have caused the too early elution of paracetamol (within the
void peak), which is unacceptable. A too low organic content,
on the other hand, led to the ASA precipitating and clogging the
tubing and the column. In the ﬁnal method, we succeeded in
ﬁnding a balance between retention and solubility by applying a
7% ACN content in the initial phase of the gradient. The peak
symmetry and selectivity were found to be better on the Zorbax
SB-C18 phase. This column was therefore chosen for the ﬁnal
method and the validation steps were carried out with this
phase. An elevated column temperature made it possible to
develop a rapid and efﬁcient method with rather low back pres-
sure (a maximum of ≏100 bar during the runs), which ensures a
longer column lifetime. The method validation was carried out
according to the current ICH guidelines. All the results satisﬁed
the guideline requirements.
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Kalmár, et al.: HPLC Determination of 4-Dimethylaminoantipyrine in Suppository Bases
Suppositories are important tools for individual therapy, especially in paediatrics, and an instrumental assay method 
has become necessary for the quality control of dosage units. The aim of this work was to develop a rapid, effective 
high-performance liquid chromatography method to assay aminophenazone in extemporaneous suppositories 
prepared with two different suppository bases, adeps solidus and massa macrogoli.  With a novel sample preparation 
method developed by the authors, 4-dimethylaminoantipyrine was determined in these suppository bases with 
95-105% recovery. The measurements were carried out on a Shimadzu Prominence ultra high-performance liquid 
chromatography system equipped with a 20 µl sample loop. The separation was achieved on a Hypersil ODS 
column, with methanol, sodium acetate buffer (pH 5.5±0.05, 0.05 M, 60:40, v/v) as the mobile phase at a flow rate 
of 1.5 ml/min. The chromatograms were acquired at 253 nm. The chromatographic method was fully validated in 
accordance with current guidelines. The presented data demonstrate the successful development of a rapid, efficient 
and robust sample preparation and high-performance liquid chromatography method for the routine quality control 
of the dosage units of suppositories containing 4-dimethylaminoantipyrine.
Key words: HPLC, validation studies, 4-dimethylantipyrine, suppositories, analytic sample preparation
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????????? ???? ?????? ??? ???? ????? ?????????? ????????? ???
???? ????????? ?????????? ??????? ??????????? ??????? ???? ???
???????????? ???? ???? ??????? ????????????????????????????
??????? ???? ??? ?????? ?????
???????????
????? ???? ?????????? ???? ???????? ???? ????? ??????
?????????????? ?????????????????????? ????????????????????
???????????????? ???? ?????????? ?????????????? ??? ???????
??????? ????? ?????? ???? ??? ??????????? ??? ??????? ?????????
????? ??????????????? ??????????????????????????
???????????
???? ???????? ??? ????????? ???? ???????????????? ???????
???? ??? ??? ???? ???????? ??????? ???? ????? ????? ??? ????
??????? ?????? ???? ???? ???????????? ??? ???? ??????? ???
???? ?????????? ????? ???? ??? ???? ?????? ??? ?????????
?????????? ?????????????? ???????? ??? ???? ???????????
???????????????? ????????? ?? ???????????? ????? ???? ??????
??? ???? ???????? ???? ???????? ??????? ???????? ?? ??????
?????????? ??? ????? ???? ?????????? ????? ???? ???? ?????
????????? ??? ???? ????????? ???? ??? ??? ???? ????????
?????? ????????????????????? ???? ???????????? ??????????
?????? ??? ??? ???????????????? ???? ????????????????? ?????
???? ????????????????? ???? ??????? ?????????????? ??????
???? ???? ???? ????? ????????????? ???? ????? ????? ???
?????????? ?????????? ??????????? ??????????????? ?? ?????
??????????????????????????????????????????
Condition changed (Units) t
R
 (min) N Symmetry factor
??????????????????????
45:55 2.088 3973 1.535
40:60 1.761 4074 1.434
35:65 1.616 4512 1.460
????????
5.00±0.05 1.837 3747 1.602
5.50±0.05 1.761 4074 1.434
6.00±0.05 1.846 4441 1.346
Flow rate (ml/min)
1.3 2.021 4346 1.432
1.5 1.761 4047 1.434
1.7 1.676 4117 1.405
Column temperature (°C)
25 1.785 3890 1.433
30 1.761 4074 1.434
35 1.751 4340 1.408
???????????????????????? ???????????????
Level % Adeps solidus Massa macrogoli
Replicates % Mean % RSD% Replicates % Mean % RSD%
50 1. 98.7 99.4 0.63 1. 104.10 102.5 1.56
2. 99.9 2. 100.90
3. 99.6 3. 102.40
100 1. 99.5 100.3 0.75 1. 97.40 99.7 1.99
2. 100.3 2. 100.50
3. 101.0 3. 101.10
150 1. 96.0 95.3 1.36 1. 104.60 104.9 0.42
2. 93.8 2. 105.40
3. 96.1 3. 104.70
300 1. 96.2 95.5 0.87 1. 104.60 102.7 2.43
2. 95.8 2. 103.70
3. 94.6 3. 99.90
450 1. 96.3 96.5 0.55 1. 102.80 102.5 1.49
2. 96.1 2. 103.80
3. 97.1 3. 100.80
???????????????????????????????????????????
STUDIES
Time (h) Standard solution Sample solution
Area Relative 
?????????????
Area Relative 
?????????????
0 2 903 843 - 2 076 275 -
18 2 909 154 0.2 2 075 720 0.0
24 2 904 895 0.0 2 073 721 -0.1
39 2 902 092 -0.1 2 074 466 -0.1
48 2 904 450 0.0 2 073 840 -0.1
63 2 906 272 0.1 2 074 709 -0.1
72 2 903 753 0.0 2 080 587 0.2
96 2 904 386 0.0 2 077 305 0.0
www.ijpsonline.com
36 Indian Journal of Pharmaceutical Sciences January - February 2014
??????? ??????? ??? ???? ?????????? ????? ??? ???? ??????????
???? ????? ?????????? ???? ?????????? ?????? ??? ??????????
?????? ??? ???? ?? ??????????? ??????? ??? ???? ????? ???????
???? ??????? ???????????? ???? ???? ????????? ??????? ????
?????????? ???????? ???? ???????????? ???????????????????
????????? ?????????????? ??????? ????? ??????? ??
??????????????????????
??? ???? ?????? ??? ???? ???????? ?????????? ????? ????
???????????????? ??? ???????????? ???? ???? ??????????????
???????? ??? ???? ?????????????? ?????????????????????
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???? ?????????????? ??????????????????????? ??? ???????
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??????????? ?????????? ????????? ???????????????????????
??????????? ?????????????????? ????????????? ??????????
????? ???? ????????? ?????????? ??? ????? ??? ????????? ????
???? ?????? ??????? ???????????? ??? ?????? ??? ???? ????????
????????? ????????? ???? ??????? ??? ???? ???? ?????????
???? ?????????? ????? ??? ??????? ??? ???????????? ??????? ???
????????????? ??????????? ?????????? ????????? ?????????
???? ???????????
???? ????? ?????????? ??? ????? ?????? ??????? ????? ?? ???????
????????? ???? ??????? ????????????????????????????? ????
????????????????? ????????????? ?????????? ???? ??????
?????????? ???? ???? ???????????????? ???????? ??? ???????????
?????? ??? ?????????????? ???????????????? ??? ???????
?????????? ???????????????????? ??? ??????????????????????
??????????? ??? ??????? ???? ???????????? ???????? ??? ???
????????????? ????? ???? ???? ???????? ???????? ???????? ???
????? ?????????????? ??????????? ???????? ???? ???? ???
?????????? ??????????????????
Fig. 1: Chromatograms of robustness test
Curves (a, d, g, j) show the initial condition. Curves (b, c) show the effect of column temperature variation (25°, 35°, respectively). Curves 
?????????????????????????????????????????????????? ??????????? ???????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????? ????????????????????????????????????????
(a) (b)
(c) (d)
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